<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">11414</article-id><article-id pub-id-type="doi">10.7554/eLife.11414</article-id><article-categories><subj-group subj-group-type="heading"><subject>Biochemistry</subject></subj-group><subj-group subj-group-type="display-channel"><subject>Registered Report</subject></subj-group></article-categories><title-group><article-title>Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-42300"><name><surname>Sharma</surname><given-names>Vidhu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-42151"><name><surname>Young</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-42396"><name><surname>Cavadas</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-29160"><name><surname>Owen</surname><given-names>Kate</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><collab>Reproducibility Project: Cancer Biology</collab><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution>Applied Biological Materials</institution>, <addr-line><named-content content-type="city">Richmond</named-content></addr-line>, <country>Canada</country></aff><aff id="aff2"><label>2</label><institution>University of College Dublin</institution>, <addr-line><named-content content-type="city">Dublin</named-content></addr-line>, <country>Ireland</country></aff><aff id="aff3"><label>3</label><institution>University of Virginia</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hunter</surname><given-names>Tony</given-names></name><role>Reviewing editor</role><aff id="aff4"><institution>Salk Institute</institution>, <country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Iorns</surname><given-names>Elizabeth</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Gunn</surname><given-names>William</given-names></name><aff><institution>Mendeley</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Tan</surname><given-names>Fraser</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Lomax</surname><given-names>Joelle</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Perfito</surname><given-names>Nicole</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Errington</surname><given-names>Timothy</given-names></name><aff><institution>Center for Open Science</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><author-notes><corresp id="cor1"><email>tim@cos.io</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>03</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e11414</elocation-id><history><date date-type="received"><day>17</day><month>09</month><year>2015</year></date><date date-type="accepted"><day>07</day><month>03</month><year>2016</year></date><fn><p><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Thomas</surname><given-names>SR</given-names></name><name><surname>Wardwell</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Emery</surname><given-names>CM</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Cogdill</surname><given-names>AP</given-names></name><name><surname>Barretina</surname><given-names>J</given-names></name><name><surname>Caponigro</surname><given-names>G</given-names></name><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Murray</surname><given-names>RR</given-names></name><name><surname>Salehi-Ashtiani</surname><given-names>K</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Alkan</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>JL</given-names></name><name><surname>Wilson</surname><given-names>CJ</given-names></name><name><surname>Myer</surname><given-names>VE</given-names></name><name><surname>Finan</surname><given-names>PM</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Golub</surname><given-names>T</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group>. <day>16</day><month>12</month><year iso-8601-date="2010">2010</year>. <article-title>COT drives resistance to RAF inhibition through MAP kinase pathway reactivation</article-title>.<source>Nature</source>. <volume>468</volume>:<fpage>968</fpage><lpage>972</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature09627</pub-id>.</mixed-citation></p></fn></history><permissions><copyright-statement>© 2016, Sharma et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Sharma et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-11414-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.11414.001</object-id><p>The <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/home/">Reproducibility Project: Cancer Biology</ext-link> seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/studies/">citations and Altmetric scores</ext-link> (<xref ref-type="bibr" rid="bib4">Errington et al., 2014</xref>). This Registered Report describes the proposed replication plan of key experiments from “COT drives resistance to RAF inhibition through MAPK pathway reactivation” by Johannessen and colleagues, published in <italic>Nature</italic> in 2010 (<xref ref-type="bibr" rid="bib10">Johannessen et al., 2010</xref>). The key experiments to be replicated are those reported in Figures 3B, 3D-E, 3I, and 4E-F. In Figures 3B, D-E, RPMI-7951 and OUMS023 cells were reported to exhibit robust ERK/MEK activity concomitant with reduced growth sensitivity in the presence of the BRAF inhibitor PLX4720. MAP3K8 (COT/TPL2) directly regulated MEK/ERK phosphorylation, as the treatment of RPMI-7951 cells with a MAP3K8 kinase inhibitor resulted in a dose-dependent suppression of MEK/ERK activity (Figure 3I). In contrast, MAP3K8-deficient A375 cells remained sensitive to BRAF inhibition, exhibiting reduced growth and MEK/ERK activity during inhibitor treatment. To determine if RAF and MEK inhibitors together can overcome single-agent resistance, MAP3K8-expressing A375 cells treated with PLX4720 along with MEK inhibitors significantly inhibited both cell viability and ERK activation compared to treatment with PLX4720 alone, as reported in Figures 4E-F. The Reproducibility Project: Cancer Biology is collaboration between the <ext-link ext-link-type="uri" xlink:href="http://centerforopenscience.org/">Center for Open Science</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.scienceexchange.com/">Science Exchange</ext-link> and the results of the replications will be published in <italic>eLife</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11414.001">http://dx.doi.org/10.7554/eLife.11414.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>Reproducibility Project: Cancer Biology</kwd><kwd>methodology</kwd><kwd>melanoma</kwd><kwd>MAPK signaling</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Laura and John Arnold Foundation</institution></institution-wrap></funding-source><principal-award-recipient><institution>Reproducibility Project: Cancer Biology</institution></principal-award-recipient></award-group><funding-statement>The Reproducibility Project: Cancer Biology is funded by the Laura and John Arnold Foundation, provided to the Center for Open Science in collaboration with Science Exchange. The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement> </funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Activation of the canonical <underline>m</underline>itogen <underline>a</underline>ctivated <underline>p</underline>rotein <underline>k</underline>inase (MAPK) pathway occurs in response to the binding of growth factors, hormones, or neurotransmitters to receptor tyrosine kinase receptors located at the cell surface (<xref ref-type="bibr" rid="bib3">Dhomen and Marais, 2009</xref>; <xref ref-type="bibr" rid="bib12">Lopez-Bergami et al., 2008</xref>). In untransformed cells, receptor ligation induces the sequential activation of the small GTPase RAS, followed by RAF, MEK and ERK, which relays proliferative signals generated at the cell periphery into the nucleus to control cellular survival, differentiation and growth (<xref ref-type="bibr" rid="bib9">Inamdar et al., 2010</xref>; <xref ref-type="bibr" rid="bib15">Panka et al., 2006</xref>). Not surprisingly, dysregulation of MAPK signaling is common in many human cancers including melanoma. Mutations in the RAF and RAS genes (<xref ref-type="bibr" rid="bib2">Davies et al., 2002</xref>; <xref ref-type="bibr" rid="bib13">Mercer and Pritchard, 2003</xref>) that trigger constitutive activation of the MAPK pathway can result in uncontrolled cell proliferation, invasion, metastasis, survival and angiogenesis (<xref ref-type="bibr" rid="bib15">Panka et al., 2006</xref>; <xref ref-type="bibr" rid="bib19">Sharma et al., 2006</xref>; <xref ref-type="bibr" rid="bib21">Smalley et al., 2006</xref>; <xref ref-type="bibr" rid="bib22">Smalley and Herlyn, 2006</xref>).</p><p>BRAF is one of three members of the RAF family, which includes ARAF, BRAF, and CRAF (or RAF-1) (<xref ref-type="bibr" rid="bib3">Dhomen and Marais, 2009</xref>). In melanoma, BRAF represents the most commonly mutated gene in the MAPK signaling cascade where 90% of tumors carry a valine to glutamic acid transition at codon 600 (V600E) that renders BRAF constitutively active and hyperactivates the MAPK cascade (<xref ref-type="bibr" rid="bib2">Davies et al., 2002</xref>; <xref ref-type="bibr" rid="bib3">Dhomen and Marais, 2009</xref>; <xref ref-type="bibr" rid="bib14">Michaloglou et al., 2008</xref>). While preclinical and clinical studies have shown that targeting BRAF (V600E) melanomas with the use of RAF-selective inhibitors results in initial tumor regression (<xref ref-type="bibr" rid="bib6">Fedorenko et al., 2015</xref>; <xref ref-type="bibr" rid="bib7">Flaherty et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Shtivelman et al., 2014</xref>), responses to RAF inhibitors are transient, with acquired resistance triggering disease progression (<xref ref-type="bibr" rid="bib20">Shtivelman et al., 2014</xref>). Although progress has been made in the development of drugs that target RAF, the clinical outcome regarding long-term usage and the mechanisms of acquired resistance warrants further evaluation. In their study, Johannessen and colleagues sought to identify kinases involved in mediating resistance to the RAF kinase inhibitor PLX4720 (<xref ref-type="bibr" rid="bib10">Johannessen et al., 2010</xref>).</p><p>Using a kinase open reading frame (ORF) collection and a high throughput screening methodology, Johannessen and colleagues identified <italic>MAP3K8</italic> (the gene encoding <underline>c</underline>ancer <underline>o</underline>saka <underline>t</underline>hyroid (COT)/TPL2), as a driver of resistance to BRAF inhibition with PLX4720 (<xref ref-type="bibr" rid="bib10">Johannessen et al., 2010</xref>). Johannessen and colleagues first examined basal MAP3K8 expression in multiple cell lines harboring the V600E mutation (<xref ref-type="bibr" rid="bib10">Johannessen et al., 2010</xref>). As shown in Figure 3B and reported by others, RPMI-7951 and OUMS-23 cells were found to express high intrinsic levels of MAP3K8 compared to A375 cells where MAP3K8 was undetectable (<xref ref-type="bibr" rid="bib10">Johannessen et al., 2010</xref>; <xref ref-type="bibr" rid="bib16">Paraiso et al., 2012</xref>). RPMI-7951 and OUMS-23 cells also exhibited robust, undiminished ERK and MEK activity concomitant with reduced growth sensitivity in the presence of PLX4720 (Figure 3D–E; <xref ref-type="bibr" rid="bib10">Johannessen et al., 2010</xref>). This is supported by additional findings demonstrating that RPMI-7981 cells treated with the closely related BRAF inhibitor PLX4032/vemurafenib (a successor of PLX4720) also remain refractory to inhibitor treatment as assessed by annexin V staining (<xref ref-type="bibr" rid="bib16">Paraiso et al., 2012</xref>) and MTS assay (<xref ref-type="bibr" rid="bib17">Park et al., 2013</xref>). However, others have reported RPMI-7981 cells as exhibiting modest sensitivity to PLX4720 (<xref ref-type="bibr" rid="bib18">Schayowitz et al., 2012</xref>). In the latter case, ERK activity was reduced by 50% after incubation with inhibitor, although these differences in sensitivity may reflect the significantly shorter time course and experimental design used by Park and colleagues. Finally, in Figure 3I, Johannessen and colleagues determined that MAP3K8 kinase activity is required to regulate MEK/ERK activation in RPMI-7951 cells, findings that further confirm MAP3K8 is an essential upstream activator of the MEK-ERK signaling cascade (<xref ref-type="bibr" rid="bib8">George and Salmeron, 2009</xref>; <xref ref-type="bibr" rid="bib10">Johannessen et al., 2010</xref>). The key experiments outlined in Figures 3B,D,E, and 3I will be replicated in protocols 1, 2, 3, and 4.</p><p>Resistance to targeted agents, such as BRAF inhibitors, is a frequent cause of therapy failure, as noted above. Importantly, chronic BRAF inhibition can lead to cross-resistance to several BRAF-selective inhibitors, indicating that resistance is not likely to be overcome by switching to a new RAF inhibitor (<xref ref-type="bibr" rid="bib1">Corcoran et al., 2010</xref>; <xref ref-type="bibr" rid="bib24">Villanueva et al., 2011</xref>). It has been suggested previously that combination treatment with MEK and BRAF inhibitors may be useful in preventing the emergence of resistance or in overcoming resistance to single agent therapies targeting either molecule alone (<xref ref-type="bibr" rid="bib1">Corcoran et al., 2010</xref>). To examine whether the combined use of RAF and MEK inhibitors bypass MAP3K8-driven resistance, Johannessen and colleagues ectopically expressed MAP3K8 in A375 melanoma cells before treatment with BRAF inhibitor (PLX4720) alone or in combination with the MEK inhibitors CI-1040 or AZD6244. As shown in Figures 4E and 4F, both viability and ERK activation was dramatically reduced in MAP3K8-expressing cells treated with either of the combination therapies, similar to cells ectopically expressing <italic>MEK1</italic>, which remained sensitive to PLX4720 (<xref ref-type="bibr" rid="bib10">Johannessen et al., 2010</xref>). Similar results were obtained in RPMI-7951 cells expressing high basal levels of MAP3K8 treated with PLX4032 and a second MEK inhibitor AS703026 (<xref ref-type="bibr" rid="bib17">Park et al., 2013</xref>). Interestingly, overexpression of constitutively active MEK (MEK1<sup>DD</sup>) resulted in increased sensitivity to BRAF inhibition combined with AZD6244, but not CI-1040 (<xref ref-type="bibr" rid="bib10">Johannessen et al., 2010</xref>). These findings confirm that MAP3K8 is able to reactivate MAPK signaling despite BRAF inhibition and that targeting RAF and MEK in combination may be an effective anti-melanoma treatment strategy. These experiments will be replicated in Protocols 5 and 6.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Protocol 1: MAPK pathway analysis in cells expressing elevated MAP3K8</title><p>This experiment assesses the effect the RAF inhibitor, PLX4720, has on the MAPK pathway, in cells expressing elevated MAP3K8, as analyzed via Western blot. It utilizes RPMI-7951 and OUMS-23 cells, which express a high level of MAP3K8 and A375 cells, which have undetectable levels. This protocol replicates the experiments reported in Figures 3B and 3E.</p><sec id="s2-1-1"><title>Sampling</title><p>Experiment to be repeated a total of 4 times for a minimum power of 80%. The original data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.</p><list list-type="bullet"><list-item><p>See Power Calculations section for details.</p></list-item></list><p>Experiment has 3 cohorts:</p><list list-type="bullet"><list-item><p>Cohort 1: A375 cells</p></list-item><list-item><p>Cohort 2: RPMI-7951 cells</p></list-item><list-item><p>Cohort 3: OUMS-23 cells</p></list-item></list><p>Each cohort has four conditions:</p><list list-type="bullet"><list-item><p>Vehicle (DMSO)</p></list-item><list-item><p>10 µM PLX4720</p></list-item><list-item><p>1 µM PLX4720</p></list-item><list-item><p>0.1 µM PLX4720</p></list-item></list><p>Each condition will be probed with the following antibodies:</p><list list-type="bullet"><list-item><p>pERK1/2 (T202/Y204)</p></list-item><list-item><p>pERK1/2</p></list-item><list-item><p>pMEK1/2 (S217/221)</p></list-item><list-item><p>MEK1/2</p></list-item><list-item><p>MAP3K8</p></list-item><list-item><p>Actin</p></list-item></list></sec><sec id="s2-1-2"><title>Materials and reagents</title><p><table-wrap id="tblu1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th valign="top">Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>RPMI medium with L-glutamine</td><td valign="top">Cell culture</td><td>Sigma</td><td>R8758</td><td>Replaces Corning cat no. 10-040-CV. <break/>Communicated by authors.</td></tr><tr><td>MEM with L-glutamine</td><td valign="top">Cell culture</td><td>Sigma</td><td>M4655-500ML</td><td>Replaces Corning cat. No. 10-010-CV. <break/>Communicated by authors.</td></tr><tr><td>Fetal bovine serum (FBS)</td><td valign="top">Cell culture</td><td>Life Technologies</td><td>12483-020</td><td>Replaces Corning brand. <break/>Communicated by authors.</td></tr><tr><td>Pen/strep/glutamine</td><td valign="top">Cell culture</td><td>Abm</td><td>G255</td><td>Replaces Corning brand. <break/>Communicated by authors.</td></tr><tr><td>A375 cells</td><td valign="top">Cell line</td><td>ATCC</td><td>CRL-1619</td><td>Original brand not specified.</td></tr><tr><td>RPMI-7951 cells</td><td valign="top">Cell line</td><td>ATCC</td><td>HTB-66</td><td/></tr><tr><td>OUMS-23 cells</td><td valign="top">Cell line</td><td>JCRB</td><td>JCRB1022</td><td>Original brand not specified.</td></tr><tr><td>6-well plates</td><td valign="top">Labware</td><td>Greiner bio-one</td><td>657 160</td><td>Original brand not specified.</td></tr><tr><td>Phosphate buffered saline (PBS)</td><td valign="top">Buffer</td><td>Sigma</td><td>D8537-500ML</td><td>Original brand not specified.</td></tr><tr><td>Trypsin</td><td valign="top">Cell culture</td><td>Sigma</td><td>T4049</td><td>Original brand not specified.</td></tr><tr><td>10 cm plates</td><td valign="top">Labware</td><td valign="top">CellStar</td><td valign="top">664 160</td><td>Original brand not specified.</td></tr><tr><td>PLX4720</td><td valign="top">Inhibitor</td><td>Selleck Chemicals</td><td>S1152</td><td>Replaces Symansis brand.</td></tr><tr><td>DMSO</td><td valign="top">Chemical</td><td>Sigma</td><td>D4540</td><td>Original brand not specified.</td></tr><tr><td>NP-40 buffer</td><td valign="top">Buffer</td><td>Life tech</td><td>FNN0021</td><td>Original brand not specified.</td></tr><tr><td>Protease inhibitors</td><td valign="top">Inhibitor</td><td>Roche</td><td>04693116001</td><td>Original catalog # not specified.</td></tr><tr><td>Phosphatase inhibitor cocktail I</td><td valign="top">Inhibitor</td><td>Sigma</td><td>P2850</td><td>Replaces CalBioChem brand.</td></tr><tr><td>Phosphatase inhibitor cocktail II</td><td valign="top">Inhibitor</td><td>Sigma</td><td>P5726</td><td>Replaces CalBioChem brand.</td></tr><tr><td>Cell scraper</td><td valign="top">Labware</td><td>Sarstedt</td><td>83.1830</td><td>Original brand not specified.</td></tr><tr><td>BCA kit</td><td valign="top">Reporter assay</td><td>Pierce</td><td>23227</td><td>Original catalog # not specified. <break/>Communicated by authors.</td></tr><tr><td>Dithiothreitol (DTT)</td><td valign="top">Chemical</td><td>Biobasic</td><td>DB0058</td><td>Original brand not specified.</td></tr><tr><td>Sample buffer</td><td valign="top">Buffer</td><td>Abm</td><td>G031</td><td>Replaces Invitrogen brand.</td></tr><tr><td>Protein molecular weight ladder</td><td valign="top">Western materials</td><td>Abm</td><td>G252, G494</td><td>Original brand not specified.</td></tr><tr><td>10% Tris/Glycine gel; <break/>10 well, 1.0 mm thick</td><td valign="top">Western materials</td><td>Abm</td><td>Internal</td><td>Replaces Invitrogen brand.</td></tr><tr><td>Running buffer</td><td valign="top">Buffer</td><td>Abm</td><td>Internal</td><td>Original brand not specified.</td></tr><tr><td>Immobilon P</td><td valign="top">Western materials</td><td>Thermofisher</td><td>IPVH00010</td><td>Original brand not specified.</td></tr><tr><td>Transfer buffer</td><td valign="top">Buffer</td><td>Abm</td><td>Internal</td><td>Original brand not specified.</td></tr><tr><td>Mouse anti-pERK1/2 <break/>(T202/Y204) (clone E10) <break/>antibody (clone E10)</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>9106</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Rabbit anti-pMEK1/2 <break/>(S217/221) (clone 41G9) <break/>antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>9154</td><td>Use at 1:11000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Mouse anti-p44/42 MAPK <break/>(ERK1/2) (clone L34F12) <break/>antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>4696</td><td>Use at 1:11000 dilution. <break/>Replaces catalog # 4695. <break/>Communicated by authors.</td></tr><tr><td>Rabbit anti-MEK1/2 <break/>(clone D1A5) antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>8727</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Rabbit anti-MAP3K8 <break/>(clone M-20) antibody</td><td valign="top">Antibodies</td><td>Santa Cruz</td><td>sc-720</td><td>Use at 1:500 dilution. <break/>Communicated by authors.</td></tr><tr><td>Mouse anti-ß-Actin <break/>(clone C4) antibody</td><td valign="top">Antibodies</td><td>Santa Cruz</td><td>sc-47778</td><td>Use at 1:100 – 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Anti-rabbit IgG – HRP <break/>conjugated antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>7074</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Anti-mouse IgG – HRP <break/>conjugated antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>7076</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Chemiluminescent reagent</td><td valign="top">Western materials</td><td>Life Technologies</td><td>WP20005</td><td>Replaces Pierce brand.</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-1-3"><title>Procedure</title><p>Note:</p><list list-type="bullet"><list-item><p>A375 cells maintained in RPMI medium supplemented with 10% FBS and 1% penicillin/streptomycin/L-glutamine at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>RPMI-7951 and OUMS-23 cells maintained in MEM medium supplemented with 10% FBS and 1% penicillin/streptomycin/L-glutamine at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>Cells will be sent for mycoplasma testing and STR profiling.</p></list-item></list><list list-type="order"><list-item><p>Plate 500,000 A375 cells, 750,000 RPMI-7951, and 750,000 OUMS-23 cells in 6-well plates and incubate for 24–36 hr to achieve log phase growth.</p></list-item><list-item><p>24–36 hr after seeding treat cells with 0.1, 1, and 10 µM PLX4720 or DMSO. Incubate for 24 hr.<list list-type="alpha-lower"><list-item><p>Add drug directly to each well using a 1000X stock (in DMSO).<list list-type="roman-lower"><list-item><p>Final DMSO concentration kept to 0.1%.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Wash cells with 1–2 ml ice-cold PBS and lyse in 1% NP-40 lysis buffer supplemented with 2X protease inhibitors and 1X phosphatase inhibitor cocktails I and II.<list list-type="alpha-lower"><list-item><p>Add ~100–200 µl 1% NP-40 lysis buffer to ensure that protein concentration is between 2–3 µg/µl.</p></list-item><list-item><p>b. Scrape each plate with a rubber cell scraper, collect lysates, and clarify by centrifugation at max speed (table-top microfuge) at 4˚C.</p></list-item></list></p></list-item><list-item><p>Determine protein concentration by BCA assay, normalize, reduce with DTT, and denature at 88˚C.</p></list-item><list-item><p>Separate 35–50 μg of protein per lane on a 10% Tris/Glycine gel with protein ladder following replicating lab’s standard protocol.<list list-type="alpha-lower"><list-item><p>Samples run per gel:<list list-type="roman-lower"><list-item><p>Protein molecular weight marker</p></list-item><list-item><p>Vehicle (DMSO) treated A375 cells</p></list-item><list-item><p>10 µM PLX4720 treated A375 cells</p></list-item><list-item><p>1 µM PLX4720 treated A375 cells</p></list-item><list-item><p>0.1 µM PLX4720 treated A375 cells</p></list-item><list-item><p>Vehicle (DMSO) treated RPMI-7951 cells</p></list-item><list-item><p>10 µM PLX4720 treated RPMI-7951 cells</p></list-item><list-item><p>1 µM PLX4720 treated RPMI-7951 cells</p></list-item><list-item><p>0.1 µM PLX4720 treated RPMI-7951 cells</p></list-item><list-item><p>Vehicle (DMSO) treated OUMS-23 cells</p></list-item><list-item><p>10 µM PLX4720 treated OUMS-23 cells</p></list-item><list-item><p>1 µM PLX4720 treated OUMS-23 cells</p></list-item><list-item><p>0.1 µM PLX4720 treated OUMS-23 cells</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Wet transfer with supplied wet-transfer cassette apparatus to immobilon P following replicating lab’s standard protocol.<list list-type="alpha-lower"><list-item><p>Original transfer protocol was for 120min at 30–35 V at 4˚C.</p></list-item></list></p></list-item><list-item><p>After transfer, block non-specific binding and immunoblot membrane with the following primary antibodies for 18 at 4˚C following manufacturer recommendations:<list list-type="alpha-lower"><list-item><p>mouse anti-pERK1/2 (T202/Y204); use at 1:1000 dilution; 42, 44 kDa</p></list-item><list-item><p>mouse anti-ERK1/2; use at 1:1000 dilution; 42, 44 kDa</p></list-item><list-item><p>rabbit anti-pMEK1/2 (S217/221); use at 1:1000 dilution; 45 kDa</p></list-item><list-item><p>rabbit anti-MEK1/2; use at 1:1000 dilution; 45 kDa</p></list-item><list-item><p>rabbit anti- MAP3K8; use at 1:500 dilution; 52, 58 kDa</p></list-item><list-item><p>mouse anti-ß-Actin; use at 1:100 - 1:1000 dilution; 43 kDa</p></list-item></list><table-wrap id="tblu2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="5"><p>Protocol 1 Western Blot Antibody</p></th></tr><tr><th/><th colspan="2">POI</th><th colspan="2">Loading Control</th></tr><tr><th>Independent Gels</th><th>Description</th><th>Working Conc.</th><th>Description</th><th>Working Conc.</th></tr></thead><tbody><tr><td>1</td><td>Mouse anti-pERK1/2 (T202/Y204) (42, 44kDa)</td><td>1:1000</td><td>Rabbit anti-MEK1/2 (45 kDa)</td><td>1:1000</td></tr><tr><td>2</td><td>Rabbit anti-pMEK1/2 (S217/221) (45 kDa)</td><td>1:1000</td><td>Mouse anti-ERK1/2 (42, 44 kDa)</td><td>1:1000</td></tr><tr><td>3</td><td>Rabbit anti-MAP3K8 (52, 58 kDa)</td><td>1:500</td><td>Mouse anti-ß-Actin (43 kDa)</td><td>1:100 – 1:1000</td></tr></tbody></table></table-wrap></p></list-item><list-item><p>Apply appropriate HRP-linked secondary antibodies for 1 hr at RT with constant agitation, and then detect signal using chemiluminescence following manufacturer’s instructions.<list list-type="alpha-lower"><list-item><p>Note: If a Li-COR Odyssey imaging system is available for use, IR Dye-labeled secondary antibodies and a low fluorescence membrane will be used instead, and images will be acquired following manufacturer’s instructions.</p></list-item></list></p></list-item><list-item><p>Analyze bands with image analysis software and normalize to loading controls.<list list-type="alpha-lower"><list-item><p>pERK1/2 (T202/Y204) normalized to MEK1/2 (total).</p></list-item><list-item><p>pMEK1/2 (S217/221) normalized to ERK1/2 (total).</p></list-item><list-item><p>MAP3K8 normalized to Actin.</p></list-item></list></p></list-item><list-item><p>Repeat steps 1–9 independently three additional times.</p></list-item></list></sec><sec id="s2-1-4"><title>Deliverables:</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Full image western blot films of all immunoblots including ladder. (Compare to Figures 3B and 3E)</p></list-item><list-item><p>Raw data of band analysis and normalized bands for each sample.</p></list-item></list></p></list-item></list></sec><sec id="s2-1-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data:<list list-type="bullet"><list-item><p>Two-way MANOVA of normalized pERK1/2 and pMEK1/2 levels of A375, RPMI-7951, and OUMS-23 cells with the following planned comparisons using the Bonferroni correction:<list list-type="bullet"><list-item><p>Planned contrast of normalized pERK1/2 levels from A375 cells treated with vehicle compared to cells treated with PLX4720 (all doses).</p></list-item><list-item><p>Planned contrast of normalized pERK1/2 levels from RPMI-7951 cells treated with vehicle compared to cells treated with PLX4720 (all doses).</p></list-item><list-item><p>Planned contrast of normalized pERK1/2 levels from OUMS-23 cells treated with vehicle compared to cells treated with PLX4720 (all doses).</p></list-item><list-item><p>Planned contrast of normalized pMEK1/2 levels from A375 cells treated with vehicle compared to cells treated with PLX4720 (all doses).</p></list-item><list-item><p>Planned contrast of normalized pMEK1/2 levels from RPMI-7951 cells treated with vehicle compared to cells treated with PLX4720 (all doses).</p></list-item><list-item><p>Planned contrast of normalized pMEK1/2 levels from OUMS-23 cells treated with vehicle compared to cells treated with PLX4720 (all doses).</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>The replication data (mean and 95% confidence interval) will be plotted with the original reported data value plotted as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></sec><sec id="s2-1-6"><title>Known differences from the original study</title><p>The replication will not include the other BRAF (V600E) cell lines reported in the original paper. The original NP40 cell lysis buffer was composed of: 150 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA pH 8, 25 mM NaF, and 1% NP-40. The replication will use a commercial formula, which has the following composition: 250 mM NaCl, 50 mM Tris pH 7.4, 5 mM EDTA, 50 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, and 1% NP-40. The western blots will use Actin, instead of Vinculin, which was reported in Figure 3B. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-1-7"><title>Provisions for quality control</title><p>The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/lmhjg/">https://osf.io/lmhjg/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-2"><title>Protocol 2: Determine the range of detection of the replicating lab’s plate reader</title><p>This is a general protocol that determines the range of detection of the plate reader in order to calculate the required number of A375, RPMI-7951, and OUMS-23 cells to yield 90–95% confluency in 5 days for Protocols 3 and 5.</p><sec id="s2-2-1"><title>Sampling</title><p>This experiment is performed a total of once with three cell lines (A375, RPMI-7951, and OUMS-23 cells).</p><p>Each cell line has 5 conditions to be performed with six technical replicates per experiment:</p><list list-type="bullet"><list-item><p>A375 cells:<list list-type="bullet"><list-item><p>1600 cells/well</p></list-item><list-item><p>1400 cells/well</p></list-item><list-item><p>1200 cells/well</p></list-item><list-item><p>1000 cells/well</p></list-item><list-item><p>800 cells/well</p></list-item></list></p></list-item><list-item><p>RPMI-7951 cells<list list-type="bullet"><list-item><p>3400 cells/well</p></list-item><list-item><p>3200 cells/well</p></list-item><list-item><p>3000 cells/well</p></list-item><list-item><p>2800 cells/well</p></list-item><list-item><p>2600 cells/well</p></list-item></list></p></list-item><list-item><p>OUMS-23 cells<list list-type="bullet"><list-item><p>3400 cells/well</p></list-item><list-item><p>3200 cells/well</p></list-item><list-item><p>3000 cells/well</p></list-item><list-item><p>2800 cells/well</p></list-item><list-item><p>2600 cells/well</p></list-item></list></p></list-item></list></sec><sec id="s2-2-2"><title>Materials and reagents</title><p><table-wrap id="tblu3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent</th><th valign="top">Type</th><th valign="top">Manufacturer</th><th valign="top">Catalog #</th><th valign="top">Comments</th></tr></thead><tbody><tr><td>RPMI medium with L-glutamine</td><td valign="top">Cell culture</td><td>Sigma</td><td>R8758</td><td>Replaces Corning cat no. 10-040-CV.</td></tr><tr><td>MEM with L-glutamine</td><td valign="top">Cell culture</td><td>Sigma</td><td>M4655-500ML</td><td>Replaces Corning cat. no. 10-010-CV.</td></tr><tr><td valign="top">FBS</td><td valign="top">Cell culture</td><td>Life Technologies</td><td>12483-020</td><td>Replaces Corning brand.</td></tr><tr><td valign="top">Pen/strep/glutamine</td><td valign="top">Cell culture</td><td>Abm</td><td>G255</td><td>Replaces Corning brand.</td></tr><tr><td valign="top">A375 cells</td><td valign="top">Cell line</td><td>ATCC</td><td>CRL-1619</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">RPMI-7951 cells</td><td valign="top">Cell line</td><td>ATCC</td><td>HTB-66</td><td valign="top"/></tr><tr><td>OUMS-23 cells</td><td valign="top">Cell line</td><td>JCRB</td><td>JCRB1022</td><td>Original brand not specified.</td></tr><tr><td valign="top">PBS</td><td valign="top">Buffer</td><td>Sigma</td><td>D8537-500ML</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">Trypsin</td><td valign="top">Cell culture</td><td>Sigma</td><td>T4049</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">10 cm plates</td><td valign="top">Labware</td><td valign="top">CellStar</td><td valign="top">664 160</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">96 well clear plates</td><td valign="top">Labware</td><td valign="top">Sarstedt</td><td valign="top">83.3924</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">WST1 viability assay</td><td valign="top">Reporter assay</td><td valign="top">Roche</td><td valign="top">11644807001</td><td valign="top">Original catalog # not specified.</td></tr><tr><td valign="top">Microplate reader (420–480 nm)</td><td valign="top">Instrument</td><td valign="top">Molecular Devices</td><td valign="top">abm</td><td valign="top">Original brand not specified.</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-2-3"><title>Procedure</title><p>Note:</p><list list-type="bullet"><list-item><p>A375 cells maintained in RPMI medium supplemented with 10% FBS and 1% penicillin/streptomycin/L-glutamine at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>RPMI-7951 and OUMS-23 cells maintained in MEM medium supplemented with 10% FBS and 1% penicillin/streptomycin/L-glutamine at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>Cells will be sent for mycoplasma testing and STR profiling.</p></list-item></list><list list-type="order"><list-item><p>Plate 800 – 1600 A375 cells, 2600 – 3400 RPMI-7951 cells, and 2600 – 3400 OUMS-23 cells in 96 well plates with 100 µl of medium. Incubate for 5 days.<list list-type="alpha-lower"><list-item><p>Plate media alone (no cells) in columns 1 and 12.</p></list-item><list-item><p>Plate cells in remaining wells (columns 2–11).</p></list-item><list-item><p>Exclude plating in the first and last row to avoid edge effects and evaporation.</p></list-item></list></p></list-item><list-item><p>5 days later estimate confluency and determine cell viability with the WST1 viability assay according to manufacturer’s instructions. Briefly described:<list list-type="alpha-lower"><list-item><p>Add 11 µl/well reagent WST-1 (1:10 dilution).</p></list-item><list-item><p>Incubate cells for 20–30 min.</p></list-item><list-item><p>Shake thoroughly for 1 min on a shaker.</p></list-item><list-item><p>Measure the absorbance against a background control as blank using a microplate reader at 420–480 nm. (If reference wavelength is to be determined, a filter &gt;600 nm is recommended)</p></list-item><list-item><p>Exclude rows A-H due to edge effects/evaporation, thus making each seeding six technical replicates.</p></list-item><list-item><p>Calculate viability after background subtraction.</p></list-item><list-item><p>Use starting cell numbers that give ~90–95% confluency in 5 days and is in the linear range of the viability assay.<list list-type="roman-lower"><list-item><p>Original report used 1500 A375 cells, 3000 RPMI-7951 cells, and 3000 OUMS-23 cells.</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-2-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Raw data and background subtracted absorbance at 420–480 nm.</p></list-item></list></p></list-item></list></sec><sec id="s2-2-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>n/a</p></list-item></list></sec><sec id="s2-2-6"><title>Known differences from the original study</title><p>All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-2-7"><title>Provisions for quality control</title><p>The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. This All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/lmhjg/">https://osf.io/lmhjg/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-3"><title>Protocol 3: PLX4720 growth inhibitory analysis in cells expressing elevated MAP3K8</title><p>This experiment assesses the effect the RAF inhibitor, PLX4720, has on cellular viability, in cells expressing elevated MAP3K8. It utilizes RPMI-7951 and OUMS-23 cells, which express a high level of MAP3K8 and A375 cells, which have undetectable levels. This protocol replicates the experiment reported in Figure 3D.</p><sec id="s2-3-1"><title>Sampling</title><p>Experiment to be repeated a total of 3 times for a minimum power of 80%. The original data is from a single biological replicate, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.</p><list list-type="bullet"><list-item><p>See Power Calculations section for details.</p></list-item></list><p>Experiment has 3 cohorts:</p><list list-type="bullet"><list-item><p>Cohort 1: A375 cells</p></list-item><list-item><p>Cohort 2: RPMI-7951 cells</p></list-item><list-item><p>Cohort 3: OUMS-23 cells</p></list-item></list><p>Each cohort has 9 conditions to be performed with six technical replicates per experiment:</p><list list-type="bullet"><list-item><p>DMSO (vehicle)</p></list-item><list-item><p>100 µM PLX4720</p></list-item><list-item><p>10 µM PLX4720</p></list-item><list-item><p>1 µM PLX4720</p></list-item><list-item><p>0.1 µM PLX4720</p></list-item><list-item><p>0.01 µM PLX4720</p></list-item><list-item><p>0.001 µM PLX4720</p></list-item><list-item><p>0.0001 µM PLX4720</p></list-item><list-item><p>0.00001 µM PLX4720</p></list-item></list></sec><sec id="s2-3-2"><title>Materials and reagents</title><p><table-wrap id="tblu4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent</th><th valign="top">Type</th><th valign="top">Manufacturer</th><th valign="top">Catalog #</th><th valign="top">Comments</th></tr></thead><tbody><tr><td>RPMI medium with <break/>L-glutamine</td><td valign="top">Cell culture</td><td>Sigma</td><td>R8758</td><td>Replaces Corning <break/>cat no. 10-040-CV.</td></tr><tr><td>MEM with L-glutamine</td><td valign="top">Cell culture</td><td>Sigma</td><td>M4655-500ML</td><td>Replaces Corning <break/>cat. no. 10-010-CV.</td></tr><tr><td valign="top">FBS</td><td valign="top">Cell culture</td><td>Life Technologies</td><td>12483-020</td><td>Replaces Corning brand.</td></tr><tr><td valign="top">Pen/strep/glutamine</td><td valign="top">Cell culture</td><td>Abm</td><td>G255</td><td>Replaces Corning brand.</td></tr><tr><td valign="top">A375 cells</td><td valign="top">Cell line</td><td>ATCC</td><td>CRL-1619</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">RPMI-7951 cells</td><td valign="top">Cell line</td><td>ATCC</td><td>HTB-66</td><td valign="top"/></tr><tr><td>OUMS-23 cells</td><td valign="top">Cell line</td><td>JCRB</td><td>JCRB1022</td><td>Original brand not specified.</td></tr><tr><td valign="top">PBS</td><td valign="top">Buffer</td><td>Sigma</td><td>D8537-500ML</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">Trypsin</td><td valign="top">Cell culture</td><td>Sigma</td><td>T4049</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">10 cm plates</td><td valign="top">Labware</td><td valign="top">CellStar</td><td valign="top">664 160</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">96 well clear plates</td><td valign="top">Labware</td><td valign="top">Sarstedt</td><td valign="top">83.3924</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">PLX4720</td><td valign="top">Inhibitor</td><td>Selleck Chemicals</td><td>S1152</td><td valign="top">Replaces Symansis brand.</td></tr><tr><td valign="top">DMSO</td><td valign="top">Chemical</td><td>Sigma</td><td>D4540</td><td valign="top">Original brand not specified.</td></tr><tr><td valign="top">WST1 viability assay</td><td valign="top">Reporter assay</td><td valign="top">Roche</td><td valign="top">11644807001</td><td valign="top">Original catalog # not specified.</td></tr><tr><td valign="top">Microplate reader <break/>(420-480 nm)</td><td valign="top">Instrument</td><td valign="top">Molecular Devices</td><td valign="top">abm</td><td valign="top">Original brand not specified.</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-3-3"><title>Procedure</title><p>Note:</p><list list-type="bullet"><list-item><p>A375 cells maintained in RPMI medium supplemented with 10% FBS and 1% penicillin/streptomycin/L-glutamine at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>RPMI-7951 and OUMS-23 cells maintained in MEM medium supplemented with 10% FBS and 1% penicillin/streptomycin/L-glutamine at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>Cells will be sent for mycoplasma testing and STR profiling.</p></list-item></list><list list-type="order"><list-item><p>Plate number of A375, RPMI-7951, and OUMS-23 cells as determined in Protocol 2 in a 96 well plate with 90 µl of medium per well. Incubate for 24 hr.<list list-type="alpha-lower"><list-item><p>Plate media alone (no cells) in columns 1 and 12.</p></list-item><list-item><p>Plate cells in remaining wells (columns 2–11).</p></list-item><list-item><p>Exclude plating in the first and last row to avoid edge effects and evaporation.</p></list-item><list-item><p>One plate is needed for each cell line.</p></list-item></list></p></list-item><list-item><p>Treat cells with 10 µl of 10X serial dilutions of PLX4720 to yield final dilutions of 100 µM to 10<sup>-5</sup> µM (8 dilutions) (columns 3 through 10), or treat with DMSO (vehicle) control (columns 2 and 11). Incubate for 96 hr.<list list-type="alpha-lower"><list-item><p>Dilute stock of PLX4720 at 1000X final concentration of serial dilution stocks in DMSO (100 mM to 0.01 µM).</p></list-item><list-item><p>Dilute 1000X serial dilution stocks 1:100 in complete growth medium to yield a 10X stock (1 mM to 10<sup>-4</sup> µM) that is added directly to the 90 µl of cell/medium.<list list-type="roman-lower"><list-item><p>Final DMSO concentration kept to 0.1%.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Determine cell viability with the WST1 viability assay according to manufacturer’s instructions. Briefly described:<list list-type="alpha-lower"><list-item><p>Add 11 µl/well reagent WST-1 (1:10 dilution).</p></list-item><list-item><p>Incubate cells for 20–30 min.</p></list-item><list-item><p>Shake thoroughly for 1 min on a shaker.</p></list-item><list-item><p>Measure the absorbance against a background control as blank using a microplate reader at 420–480 nm. (If reference wavelength is to be determined, a filter &gt;600 nm is recommended)</p></list-item><list-item><p>Exclude rows A-H due to edge effects/evaporation, thus making each cohort six technical replicates, except DMSO (vehicle), which has 12.</p></list-item><list-item><p>Calculate viability as a percentage of control (DMSO (vehicle) cells) after background subtraction.</p></list-item><list-item><p>Determine GI<sub>50</sub> value by fitting data using a nonlinear regression curve fit with a sigmoid dose-response curve (four-parameter log-logistic function).</p></list-item></list></p></list-item><list-item><p>Repeat steps 1–3 independently two additional times.</p></list-item></list></sec><sec id="s2-3-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Raw data and background subtracted absorbance at 420–480 nm.</p></list-item><list-item><p>GI<sub>50</sub> values of each biological replicate.</p></list-item><list-item><p>Graph of average GI<sub>50</sub> values for each condition. (Compare to Figure 3D.)</p></list-item></list></p></list-item></list></sec><sec id="s2-3-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data:<list list-type="bullet"><list-item><p>One way ANOVA of GI<sub>50</sub> values from A375, RPMI-7951, and OUMS-23 cells with the following planned comparisons using Fisher’s LSD test.</p></list-item></list></p></list-item><list-item><p>A375 cells compared to RPMI-7951 cells.</p></list-item><list-item><p>A375 cells compared to OUMS-23 cells.</p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>The replication data (mean and 95% confidence interval) will be plotted with the original reported data value plotted as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></sec><sec id="s2-3-6"><title>Known differences from the original study</title><p>The replication will not include the other BRAF (V600E) cell lines reported in the original paper. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-3-7"><title>Provisions for quality control</title><p>The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. The seeding density of each cell line was determined in Protocol 2. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/lmhjg/">https://osf.io/lmhjg/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-4"><title>Protocol 4: MAPK pathway analysis after MAP3K8 inhibition in cells expressing elevated MAP3K8</title><p>This experiment assesses the effect a MAP3K8 kinase inhibitor has on the MAPK pathway, in cells expressing elevated MAP3K8, as analyzed via Western blot. It utilizes RPMI-7951 cells, which express a high level of MAP3K8. This protocol replicates the experiment reported in Figure 3I.</p><sec id="s2-4-1"><title>Sampling</title><p>Experiment to be repeated a total of 8 times for a minimum power of 80%. The original data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.</p><list list-type="bullet"><list-item><p>See Power Calculations section for details.</p></list-item></list><p>Experiment has five conditions:</p><list list-type="bullet"><list-item><p>Vehicle (DMSO) treated RPMI-7951 cells</p></list-item><list-item><p>20 µM MAP3K8 inhibitor treated RPMI-7951 cells</p></list-item><list-item><p>10 µM MAP3K8 inhibitor treated RPMI-7951 cells</p></list-item><list-item><p>5 µM MAP3K8 inhibitor treated RPMI-7951 cells</p></list-item><list-item><p>1 µM MAP3K8 inhibitor treated RPMI-7951 cells</p></list-item></list><p>Each condition will be probed with the following antibodies:</p><list list-type="bullet"><list-item><p>pERK1/2 (T202/Y204)</p></list-item><list-item><p>pERK1/2</p></list-item><list-item><p>pMEK1/2 (S217/221)</p></list-item><list-item><p>MEK1/2</p></list-item><list-item><p>Vinculin</p></list-item></list></sec><sec id="s2-4-2"><title>Materials and reagents</title><p><table-wrap id="tblu5" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th valign="top">Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>MEM with <break/>L-glutamine</td><td valign="top">Cell culture</td><td>Sigma</td><td>M4655-500ML</td><td>Replaces Corningcat. no. 10-010-CV</td></tr><tr><td>FBS</td><td valign="top">Cell culture</td><td>Life Technologies</td><td>12483-020</td><td>Replaces Corning brand.</td></tr><tr><td>Pen/strep/glutamine</td><td valign="top">Cell culture</td><td>Abm</td><td>G255</td><td>Replaces Corning brand.</td></tr><tr><td>RPMI-7951 cells</td><td valign="top">Cell line</td><td>ATCC</td><td>HTB-66</td><td/></tr><tr><td>PBS</td><td valign="top">Buffer</td><td>Sigma</td><td>D8537-500ML</td><td>Original brand not specified.</td></tr><tr><td>Trypsin</td><td valign="top">Cell culture</td><td>Sigma</td><td>T4049</td><td>Original brand not specified.</td></tr><tr><td>10 cm plates</td><td valign="top">Labware</td><td valign="top">CellStar</td><td valign="top">664 160</td><td>Original brand not specified.</td></tr><tr><td>6 well plates</td><td valign="top">Labware</td><td>Greiner bio-one</td><td>657 160</td><td>Original brand not specified.</td></tr><tr><td>MAP3K8 kinase inhibitor</td><td valign="top">Inhibitor</td><td>EMD</td><td>616373</td><td/></tr><tr><td>DMSO</td><td valign="top">Chemical</td><td>Sigma</td><td>D4540</td><td>Original brand not specified.</td></tr><tr><td>NP-40 buffer</td><td valign="top">Buffer</td><td>Life Technologies</td><td>FNN0021</td><td>Original brand not specified.</td></tr><tr><td>Protease inhibitors</td><td valign="top">Inhibitor</td><td>Roche</td><td>04693116001</td><td>Original catalog # <break/>not specified.</td></tr><tr><td>Phosphatase inhibitor <break/>cocktail I</td><td valign="top">Inhibitor</td><td>Sigma</td><td>P2850</td><td>Replaces CalBioChem brand.</td></tr><tr><td>Phosphatase inhibitor <break/>cocktail II</td><td valign="top">Inhibitor</td><td>Sigma</td><td>P5726</td><td>Replaces CalBioChem brand.</td></tr><tr><td>Cell scraper</td><td valign="top">Labware</td><td>Sasrstedt</td><td>83.1830</td><td>Original brand not specified.</td></tr><tr><td>BCA kit</td><td valign="top">Reporter assay</td><td>Pierce</td><td>23227</td><td>Original catalog # not specified. <break/>Communicated by authors.</td></tr><tr><td>DTT</td><td valign="top">Chemical</td><td>Biobasic</td><td>DB0058</td><td>Original brand not specified.</td></tr><tr><td>Sample buffer</td><td valign="top">Buffer</td><td>abm</td><td>G031</td><td>Replaces Invitrogen brand.</td></tr><tr><td>Protein molecular weight ladder</td><td valign="top">Western materials</td><td>abm</td><td>G252, G494</td><td>Original brand not specified.</td></tr><tr><td>10% Tris/Glycine gel; 10 well, 1.0 mm thick</td><td valign="top">Western materials</td><td>abm</td><td>internal</td><td>Replaces Invitrogen brand.</td></tr><tr><td>Running buffer</td><td valign="top">Buffer</td><td>abm</td><td>internal</td><td>Original brand not specified.</td></tr><tr><td>Immobilon P</td><td valign="top">Western materials</td><td>Thermofisher</td><td>IPVH00010</td><td>Original brand not specified.</td></tr><tr><td>Transfer buffer</td><td valign="top">Buffer</td><td>abm</td><td>internal</td><td>Original brand not specified.</td></tr><tr><td>Mouse anti-pERK1/2 <break/>(T202/Y204) (clone E10) <break/>antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>9106</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Rabbit anti-pMEK1/2 <break/>(S217/221) (clone 41G9) <break/>antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>9154</td><td>Use at 1:11000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Mouse anti-p44/42 <break/>MAPK (ERK1/2) <break/>(clone L34F12) antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>4696</td><td>Use at 1:11000 dilution. <break/>Replaces catalog # 4695. <break/>Communicated by authors.</td></tr><tr><td>Rabbit anti-MEK1/2 <break/>(clone D1A5) antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>8727</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Rabbit anti-Vinculin <break/>antibody</td><td valign="top">Antibodies</td><td>Sigma</td><td valign="top">V4139</td><td>Use at 1:20,000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Anti-rabbit IgG – HRP <break/>conjugated</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>7074</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Anti-mouse IgG – HRP <break/>conjugated</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>7076</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Chemiluminescent reagent</td><td valign="top">Western materials</td><td>Life Technologies</td><td>WP20005</td><td>Replaces Pierce brand.</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-4-3"><title>Procedure</title><p>Note:</p><list list-type="bullet"><list-item><p>RPMI-7951 cells maintained in MEM medium supplemented with 10% FBS and 1% penicillin/streptomycin at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>Cells will be sent for mycoplasma testing and STR profiling.</p></list-item></list><list list-type="order"><list-item><p>Plate 750,000 RPMI-7951 cells in 6-well plates and incubate for 24–36 hr to achieve log phase growth</p></list-item><list-item><p>Wash twice with 1X PBS and incubate overnight in serum-free growth medium.</p></list-item><list-item><p>Treat cells with 20, 10, 5, and 1 µM MAP3K8 inhibitor or DMSO for 1 hr.<list list-type="alpha-lower"><list-item><p>Add drug directly to each well.</p></list-item><list-item><p>Make stocks of MAP3K8 inhibitor at 10 mM in DMSO. (500X dilution for 20 µM)</p></list-item><list-item><p>Dilute stock of MAP3K8 to achieve 1000X final concentration of serial dilution stocks in DMSO (10 mM to 1000 µM).</p></list-item><list-item><p>Final DMSO concentration kept to 0.2%.</p></list-item></list></p></list-item><list-item><p>Wash cells with 1–2 ml ice-cold PBS and lyse in 1% NP-40 lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA pH 8, 25 mM NaF, and 1% NP-40) supplemented with 2X protease inhibitors and 1X phosphatase inhibitor cocktails I and II.<list list-type="alpha-lower"><list-item><p>Add ~100–200 µl 1% NP-40 lysis buffer to ensure that protein concentration is between 2–3 µg/µl.</p></list-item><list-item><p>Scrape each plate with a rubber cell scraper, collect lysates, and clarify by centrifugation at max speed (table-top microfuge) at 4˚C.</p></list-item></list></p></list-item><list-item><p>Determine protein concentration by BCA assay, normalize, reduce with DTT, and denature at 88˚C.</p></list-item><list-item><p>Separate 35–50 μg of protein per lane on a 10% Tris/Glycine gel with protein ladder following replicating lab’s standard protocol.<list list-type="alpha-lower"><list-item><p>Samples run per gel:<list list-type="roman-lower"><list-item><p>Protein molecular weight marker</p></list-item><list-item><p>Vehicle (DMSO) treated RPMI-7951 cells</p></list-item><list-item><p>20 µM MAP3K8 inhibitor treated RPMI-7951 cells</p></list-item><list-item><p>10 µM MAP3K8 inhibitor treated RPMI-7951 cells</p></list-item><list-item><p>5 µM MAP3K8 inhibitor treated RPMI-7951 cells</p></list-item><list-item><p>1 µM MAP3K8 inhibitor treated RPMI-7951 cells</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Wet transfer with supplied wet-transfer cassette apparatus (120 min at 30–35 V at 4˚C) to immobilon P following replicating lab’s standard protocol.</p></list-item><list-item><p>After transfer, block non-specific binding and immunoblot membrane with the following primary antibodies for 18 hr at 4˚C following manufacturer recommendations:<list list-type="alpha-lower"><list-item><p>mouse anti-pERK1/2 (T202/Y204); use at 1:1000 dilution; 42, 44 kDa</p></list-item><list-item><p>mouse anti-ERK1/2; use at 1:1000 dilution; 42, 44 kDa</p></list-item><list-item><p>rabbit anti-pMEK1/2 (S217/221); use at 1:1000 dilution; 45 kDa</p></list-item><list-item><p>rabbit anti-MEK1/2; use at 1:1000 dilution; 45 kDa</p></list-item><list-item><p>rabbit anti-Vinculin; use at 1:20,000 dilution; 116 kDa</p></list-item></list><table-wrap id="tblu6" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="5"><p>Protocol 4 Western blot antibody combinations</p></th></tr><tr><th/><th colspan="2">POI</th><th colspan="2">Loading Control</th></tr><tr><th>Independent Gels</th><th>Description</th><th>Working Conc.</th><th>Description</th><th>Working Conc.</th></tr></thead><tbody><tr><td>1</td><td>Mouse anti-pERK1/2 <break/>(T202/Y204) (42, 44 kDa)</td><td>1:1000</td><td>Rabbit anti-MEK1/2 (45 kDa)</td><td>1:1000</td></tr><tr><td>2</td><td>Rabbit anti-pMEK1/2 <break/>(S217/221) (45 kDa)</td><td>1:1000</td><td>Mouse anti-ERK1/2 (42, 44 kDa)</td><td>1:1000</td></tr><tr><td>3</td><td/><td/><td>Rabbit anti-Vinculin (116 kDa)</td><td>1:20000</td></tr></tbody></table></table-wrap></p></list-item><list-item><p>Apply appropriate HRP-linked secondary antibodies for 1 hr at RT with constant agitation, and then detect signal using chemiluminescence following manufacturer’s instructions.<list list-type="alpha-lower"><list-item><p>Note: If a Li-COR Odyssey imaging system is available for use, IR Dye-labeled secondary antibodies and a low fluorescence membrane will be used instead, and images will be acquired following manufacturer’s instructions.</p></list-item></list></p></list-item><list-item><p>Analyze bands with image analysis software, normalize to loading controls, and normalize each dose of MAP3K8 inhibitor to Vehicle (DMSO).<list list-type="alpha-lower"><list-item><p>pERK1/2 (T202/Y204) normalized to MEK1/2 (total).</p></list-item><list-item><p>pMEK1/2 (S217/221) normalized to ERK1/2 (total).</p></list-item></list></p></list-item><list-item><p>Repeat steps 1–10 independently seven additional times.</p></list-item></list></sec><sec id="s2-4-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Full image western blot films of all immunoblots including ladder. (Compare to Figure 3I)</p></list-item><list-item><p>Raw data of band analysis and normalized bands for each sample.</p></list-item></list></p></list-item></list></sec><sec id="s2-4-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data:<list list-type="bullet"><list-item><p>One-way MANOVA of normalized pERK1/2 and pMEK1/2 levels of RPMI-7951 cells treated with MAP3K8 inhibitor with the following analysis using the Bonferroni correction:<list list-type="bullet"><list-item><p>One-way ANOVA of pERK1/2 levels of RPMI-7951 cells treated with MAP3K8 inhibitor.<list list-type="bullet"><list-item><p>One-sample <italic>t</italic>-test of pERK1/2 levels of 20 µM treated cells compared to 1 (vehicle treated cells).</p></list-item></list></p></list-item><list-item><p>One-way ANOVA of pMEK1/2 levels of RPMI-7951 cells treated with MAP3K8 inhibitor.<list list-type="bullet"><list-item><p>One-sample <italic>t</italic>-test of pMEK1/2 levels of 20 µM treated cells compared to 1 (vehicle treated cells).</p></list-item></list></p></list-item></list></p></list-item><list-item><p>IC<sub>50</sub> values of normalized pERK1/2 and pMEK1/2 levels treated with vehicle or MAP3K8 inhibitor.</p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>The replication data (mean and 95% confidence interval) will be plotted with the original reported data value plotted as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></sec><sec id="s2-4-6"><title>Known differences from the original study</title><p>The original NP40 cell lysis buffer was composed of: 150 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA pH 8, 25 mM NaF, and 1% NP-40. The replication will use a commercial formula, which has the following composition: 250 mM NaCl, 50 mM Tris pH 7.4, 5 mM EDTA, 50 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, and 1% NP-40. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-4-7"><title>Provisions for quality control</title><p>The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/lmhjg/">https://osf.io/lmhjg/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-5"><title>Protocol 5: Viability analysis following combinatorial MAPK pathway inhibition in cells expressing elevated MAP3K8</title><p>This experiment assesses the effect the RAF inhibitor, PLX4720, along with the MEK inhibitors, CI-1040 or AZD6244, has on cellular viability, in cells expressing MAP3K8. It utilizes A375 cells expressing MAP3K8, via ectopic expression of <italic>MAP3K8</italic>. This protocol replicates the experiment reported in Figure 4E.</p><sec id="s2-5-1"><title>Sampling</title><p>Generation of A375 cells expressing MEK1, MEK1<sup>DD</sup>, and MAP3K8 to be performed once.</p><p>Experiment (steps 4–6) to be repeated a total of 4 times for a minimum power of 80%. The original data is from a single biological replicate, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.</p><list list-type="bullet"><list-item><p>See Power Calculations section for details.</p></list-item></list><p>Experiment has 3 cohorts:</p><list list-type="bullet"><list-item><p>Cohort 1: A375 cells expressing MEK1</p></list-item><list-item><p>Cohort 2: A375 cells expressing MEK1<sup>DD</sup></p></list-item><list-item><p>Cohort 3: A375 cells expressing MAP3K8</p></list-item></list><p>Each cohort has 6 conditions to be done with six technical repeats per experiment:</p><list list-type="bullet"><list-item><p>Untreated [additional control]</p></list-item><list-item><p>DMSO (vehicle)</p></list-item><list-item><p>10 µM PLX4720</p></list-item><list-item><p>1 µM PLX4720</p></list-item><list-item><p>1 µM PLX4720 + 1 µM AZD6244</p></list-item><list-item><p>1 µM PLX4720 + 1 µM CI-1040</p></list-item></list></sec><sec id="s2-5-2"><title>Materials and reagents</title><p><table-wrap id="tblu7" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th valign="top">Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>RPMI medium with L-glutamine</td><td valign="top">Cell culture</td><td>Sigma</td><td>R8758</td><td>Replaces Corning cat no. 10-040-CV.</td></tr><tr><td>DMEM medium</td><td valign="top">Cell culture</td><td>Corning</td><td>10-013</td><td>Original brand not specified.</td></tr><tr><td>FBS</td><td valign="top">Cell culture</td><td>Life Technologies</td><td>12483-020</td><td>Replaces Corning brand.</td></tr><tr><td>Pen/strep/glutamine</td><td valign="top">Cell culture</td><td>Abm</td><td>G255</td><td>Replaces Corning brand.</td></tr><tr><td>A375 cells</td><td valign="top">Cell line</td><td>ATCC</td><td>CRL-1619</td><td>Original brand not specified.</td></tr><tr><td>293T cells</td><td valign="top">Cell line</td><td>ATCC</td><td>CRL-11268</td><td/></tr><tr><td>PBS</td><td valign="top">Buffer</td><td>Sigma</td><td>D8537-500ML</td><td>Original brand not specified.</td></tr><tr><td>Trypsin</td><td valign="top">Cell culture</td><td>Sigma</td><td>T4049</td><td>Original brand not specified.</td></tr><tr><td>10 cm plates</td><td valign="top">Labware</td><td valign="top">CellStar</td><td valign="top">664 160</td><td>Original brand not specified.</td></tr><tr><td>6 cm plates</td><td valign="top">Labware</td><td>Biolite</td><td>11825275</td><td>Original brand not specified.</td></tr><tr><td>Nucleobond Maxiprep Kit</td><td valign="top">Kit</td><td>Macherey-Nagel</td><td>740414</td><td>Not originallyspecified</td></tr><tr><td>pLX-Blast-V5-MEK1</td><td valign="top">DNA construct</td><td colspan="3">Provided from original authors</td></tr><tr><td>pLX-Blast-V5-MEK1<sup>DD</sup></td><td valign="top">DNA construct</td><td colspan="3">Provided from original authors</td></tr><tr><td>pLX-Blast-V5-MAP3K8</td><td valign="top">DNA construct</td><td colspan="3">Provided from original authors</td></tr><tr><td>∆8.9 (gag,pol)</td><td valign="top">DNA construct</td><td colspan="3">Provided from original authors</td></tr><tr><td>VSV-G</td><td valign="top">DNA construct</td><td colspan="3">Provided from original authors</td></tr><tr><td>FuGene HD transfection reagent</td><td valign="top">Transfection reagent</td><td>Promega</td><td>E2311</td><td>Replaces FuGene6 Roche brand.</td></tr><tr><td>OptiMEM medium</td><td valign="top">Buffer</td><td>Life Tech</td><td>51985034</td><td>Original brand not specified.</td></tr><tr><td>6-well plates</td><td valign="top">Labware</td><td>Greiner bio-one</td><td>657 160</td><td>Original brand not specified.</td></tr><tr><td>Polybrene</td><td valign="top">Cell culture</td><td>Sigma</td><td>H9268</td><td>Original brand not specified.</td></tr><tr><td>Blasticidin</td><td valign="top">Cell culture</td><td>Invivogen</td><td>ant-bl-1</td><td>Original brand not specified.</td></tr><tr><td>96 well clear plates</td><td valign="top">Labware</td><td valign="top">Sarstedt</td><td valign="top">83.3924</td><td>Original brand not specified.</td></tr><tr><td>PLX4720</td><td valign="top">Inhibitor</td><td>Selleck Chemicals</td><td>S1152</td><td>Replaces Symansis brand.</td></tr><tr><td>AZD6244</td><td valign="top">Inhibitor</td><td>Selleck Chemicals</td><td>S1008</td><td>Original catalog # not specified.</td></tr><tr><td>CI-1040</td><td valign="top">Inhibitor</td><td>Selleck Chemicals</td><td>S1020</td><td>Replaces Shanghai <break/>Lechen International <break/>Trading Co. brand.</td></tr><tr><td>DMSO</td><td valign="top">Chemical</td><td>Sigma</td><td>D4540</td><td>Original brand <break/>not specified.</td></tr><tr><td>WST1 viability assay</td><td valign="top">Reporter assay</td><td valign="top">Roche</td><td valign="top">11644807001</td><td>Original catalog # <break/>not specified.</td></tr><tr><td>Microplate reader <break/>(420–480 nm)</td><td valign="top">Instrument</td><td valign="top">Molecular Devices</td><td valign="top">abm</td><td>Original brand not specified.</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-5-3"><title>Procedure</title><p>Note:</p><list list-type="bullet"><list-item><p>A375 cells maintained in RPMI medium supplemented with 10% FBS and 1% penicillin/streptomycin/L-glutamine at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>293T cells maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>Cells will be sent for mycoplasma testing and STR profiling.</p></list-item></list><list list-type="order"><list-item><p>Grow and prepare endotoxin-free plasmid constructs according to the manufacturer’s protocol for an endotoxin-free Plasmid Maxiprep Kit.<list list-type="alpha-lower"><list-item><p>Viral packaging vectors:<list list-type="roman-lower"><list-item><p>∆8.9 (gag,pol)</p></list-item><list-item><p>VSV-G</p></list-item></list></p></list-item><list-item><p>DNA construct expression vectors:<list list-type="roman-lower"><list-item><p>pLX-Blast-V5-MEK1</p></list-item><list-item><p>pLX-Blast-V5-MEK1<sup>DD</sup></p></list-item><list-item><p>pLX-Blast-V5-MAP3K8</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Sequence expression plasmids to confirm identity and run on gel to confirm vector integrity. Use the following sequencing primers to confirm the identify of the pLX_CMV plasmids:<list list-type="alpha-lower"><list-item><p>pLX_CMV-ORF-fwd primer: 5’-CACCAAAATCAACGGGACTT-3’</p></list-item><list-item><p>pLX-ORF-rev primer: 5’-AGGAGGAGAAAATGAAAGCC-3’</p></list-item></list></p></list-item><list-item><p>Produce MEK1, MEK1<sup>DD</sup>, and MAP3K8 lentivirus:<list list-type="alpha-lower"><list-item><p>Seed 8 x 10<sup>5</sup> 293T cells per 6 cm dish, incubate.</p></list-item><list-item><p>24 hr later, transfect each plate of 293T cells by adding the following:<list list-type="roman-lower"><list-item><p>1 µg pLX-Blast-V5-MEK1, pLX-Blast-V5-MEK1<sup>DD</sup>, or pLX-Blast-V5-MAP3K8</p></list-item><list-item><p>900 ng ∆8.9 (gag,pol)</p></list-item><list-item><p>100 ng VSV-G</p></list-item><list-item><p>6 µl FuGene transfection reagent</p></list-item><list-item><p>94 µl OptiMem medium (free of FBS and Pen/Strep). Add OptiMem medium to the aliquots of DNA, then add the FuGene to the OptiMem/DNA mix.</p></list-item><list-item><p>Incubate 30 min at RT, then add to cells.</p></list-item></list></p></list-item><list-item><p>Harvest virus 72 hr post-transfection, aliquot, and freeze at -80˚C for at least 24 hr before using.<list list-type="roman-lower"><list-item><p>Note: You will need to freeze down enough virus for both Protocols 5 and 6.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Titrate lentivirus:<list list-type="alpha-lower"><list-item><p>Seed 100,000 – 125,000 A375 cells per well in 6 well plates in 2 ml medium. Incubate for 24 hr in normal growth conditions.<list list-type="roman-lower"><list-item><p>Seeding density is such that cells will be near confluent 3 days after removing virus.</p></list-item><list-item><p>Seed two wells per viral concentration for each virus (total wells = 30).</p></list-item></list></p></list-item><list-item><p>Add polybrene (4–10 µg/ml final concentration) to plates, swirl to mix, then infect cells with varying concentrations of virus (1:5, 1:10, 1:12, 1:15, and 1:20) in duplicate (i.e. two wells per viral concentration).<list list-type="roman-lower"><list-item><p>Thaw virus overnight at 4˚C, or in a 37˚C water bath, but without letting the virus get above 4˚C.</p></list-item><list-item><p>Add virus to the wells and swirl to mix.</p></list-item><list-item><p>Spin 6-well plates at 2250 RPM for 30 min at 37˚C.</p></list-item><list-item><p>Incubate cells overnight with virus, then change medium the following morning.</p></list-item></list></p></list-item><list-item><p>Incubate for 24 hr, then remove medium and replace with growth medium with or without 10 µg/ml blasticidin.</p></list-item><list-item><p>After 5–7 days of selection, count the cells in all wells and divide the counts with blasticidin by the non-selected control for each viral dilution.</p></list-item><list-item><p>Use the lowest viral dilution that yields an 85–95% ratio of selected/non-selected cells (originally observed to be in the 1:8 – 1:15 range).</p></list-item></list></p></list-item><list-item><p>Infect A375 cells with viral supernatant:<list list-type="alpha-lower"><list-item><p>Seed 100,000 – 125,000 A375 cells per well in 6 well plates in 2 ml medium. Incubate for 24 hr in normal growth conditions.<list list-type="roman-lower"><list-item><p>Seed three wells per virus. (total wells = 9).</p></list-item></list></p></list-item><list-item><p>Add polybrene (4–10 µg/ml final concentration) to plates, swirl to mix, then infect cells with dilution determined by titration protocol (step 4 above).<list list-type="roman-lower"><list-item><p>Thaw virus overnight at 4˚C, or in a 37˚C water bath, but without letting the virus get above 4˚C.</p></list-item><list-item><p>Add virus to the wells and swirl to mix.<list list-type="order"><list-item><p>Alternatively, make a 3X virus/polybrene mixture, such that the addition of 1 ml of 3X virus to 2 ml of cells/medium yields an appropriate dilution of virus and polybrene.</p></list-item></list></p></list-item><list-item><p>Spin 6-well plates at 2250 RPM for 30 min at 37˚C.</p></list-item><list-item><p>Incubate cells overnight with virus, then change medium the following morning.</p></list-item></list></p></list-item><list-item><p>Incubate for 24 hr, then remove medium and replace with growth medium with or without 10 µg/ml blasticidin.<list list-type="roman-lower"><list-item><p>Two wells without selection and one well with blasticidin for each virus.</p></list-item></list></p></list-item><list-item><p>After 5–7 days of selection, count cells in one well of no-blasticidin and the blasticidin-treated well to calculate infection efficiency.<list list-type="roman-lower"><list-item><p>Divide the counts with blasticidin by the non-selected control.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>After 48 hr trypsinize the experimental wells (one per virus), count, and plate number of A375 infected cells as determined in Protocol 2 in a 96 well plate in 90 µl. Incubate for 24 hr.<list list-type="alpha-lower"><list-item><p>Plate media alone (no cells) in columns 1,2,11, and 12.</p></list-item><list-item><p>Plate cells in remaining wells (columns 3–10).</p></list-item><list-item><p>Exclude plating in the first and last row to avoid edge effects and evaporation.</p></list-item><list-item><p>One plate is needed for each of the A375 infected cells.</p></list-item></list></p></list-item><list-item><p>Treat cells with 10 µl of 10X dilutions of PLX4720 with or without AZD6244 or CI-1040 to yield appropriate final concentrations (columns 5 through 8), or treat with DMSO (vehicle) control (columns 4 and 9). Add 10 µl medium for untreated control (columns 3 and 10). Incubate for 96 hr.<list list-type="alpha-lower"><list-item><p>Dilute stock of PLX4720 at 1000X final concentration in DMSO (10 mM and 1 mM).</p></list-item><list-item><p>Dilute stock of AZD6244 and CI-1040 at 1000X final concentration in DMSO (1 mM).</p></list-item><list-item><p>Dilute 1000X dilution stocks 1:100 in complete growth medium to yield a 10X stock of appropriate treatment.<list list-type="roman-lower"><list-item><p>Final DMSO concentration kept to 0.2%.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Determine cell viability with the WST1 viability assay according to manufacturer’s instructions. Briefly described:<list list-type="alpha-lower"><list-item><p>Add 11 µl/well reagent WST-1 (1:10 dilution).</p></list-item><list-item><p>Incubate cells for 20–30 min.</p></list-item><list-item><p>Shake thoroughly for 1 min on a shaker.<list list-type="roman-lower"><list-item><p>Measure the absorbance against a background control as blank using a microplate reader at 420–480 nm. (If reference wavelength is to be determined, a filter &gt; 600 nm is recommended)</p></list-item></list></p></list-item><list-item><p>Exclude rows A-H due to edge effects/evaporation, thus making each cohort six technical replicates, except DMSO (vehicle) and untreated control, which has 12.</p></list-item><list-item><p>Calculate viability as a percentage of control (DMSO(vehicle) cells) after background subtraction.</p></list-item></list></p></list-item><list-item><p>Repeat steps 5–8 independently three additional times.</p></list-item></list></sec><sec id="s2-5-4"><title>Deliverables:</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Raw counts and titration percentages (step 2 above).</p></list-item><list-item><p>Raw counts and infection efficiency (step 3 above).</p></list-item><list-item><p>Raw data and background subtracted absorbance at 420–480 nm.</p></list-item><list-item><p>Relative viability of A375 cells expressing MEK1, MEK1<sup>DD</sup>, and MAP3K8 as a percentage of DMSO treatment for each cell line. (Compare to Figure 4E.)</p></list-item></list></p></list-item><list-item><p>Sample for additional protocol:<list list-type="bullet"><list-item><p>MEK1, MEK1<sup>DD</sup>, and MAP3K8 lentivirus for further use (Protocol 6).</p></list-item></list></p></list-item></list></sec><sec id="s2-5-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data:<list list-type="bullet"><list-item><p>One-way ANOVA of normalized viability of A375 cells expressing MAP3K8 treated with vehicle, 1 µM PLX4720, 1 µM PLX4720 + CI-1040, 1 µM PLX4720 + AZD6244, or 10 µM PLX4720 with the following planned comparisons using the Bonferroni correction:<list list-type="bullet"><list-item><p>1 µM PLX4720 treatment compared to 1 µM PLX4720 + CI-1040.</p></list-item><list-item><p>1 µM PLX4720 treatment compared to 1 µM PLX4720 + AZD6244.</p></list-item><list-item><p>10 µM PLX4720 treatment compared to 1 µM PLX4720 + CI-1040.</p></list-item><list-item><p>10 µM PLX4720 treatment compared to 1 µM PLX4720 + AZD6244.</p></list-item></list></p></list-item><list-item><p>Two-way ANOVA of normalized viability of A375 cells expressing MEK1 or MEK1<sup>DD</sup> treated with vehicle, 1 µM PLX4720, 1 µM PLX4720 + CI-1040, 1 µM PLX4720 + AZD6244, or 10 µM PLX4720.</p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>The replication data (mean and 95% confidence interval) will be plotted with the original reported data value plotted as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></sec><sec id="s2-5-6"><title>Known differences from the original study</title><p>All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-5-7"><title>Provisions for quality control</title><p>The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. The seeding density of the A375 cell line was determined in Protocol 2. Infection efficiency will be determined for each replicate. The expression of the kinase of interest will be assessed using antibodies against the V5 tag as well as MAP3K8 and MEK1 as described in Protocol 6. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/lmhjg/">https://osf.io/lmhjg/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-6"><title>Protocol 6 MAPK pathway analysis following combinatorial MAPK pathway inhibition in cells expressing elevated MAP3K8</title><p>This experiment assesses the effect the RAF inhibitor, PLX4720, along with the MEK inhibitors, CI-1040 or AZD6244, has on the MAPK pathway, as analyzed via Western blot. It utilizes A375 cells expressing MAP3K8, via ectopic expression of <italic>MAP3K8</italic>. This protocol replicates the experiment reported in Figure 4F.</p><sec id="s2-6-1"><title>Sampling</title><p>Experiment to be repeated a total of 3 times for a minimum power of 80%. The original data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.</p><list list-type="bullet"><list-item><p>See Power Calculations section for details.</p></list-item></list><p>Experiment has 3 cohorts:</p><list list-type="bullet"><list-item><p>Cohort 1: A375 cells expressing MEK1</p></list-item><list-item><p>Cohort 2: A375 cells expressing MEK1<sup>DD</sup></p></list-item><list-item><p>Cohort 3: A375 cells expressing MAP3K8</p></list-item></list><p>Each cohort has 4 conditions:</p><list list-type="bullet"><list-item><p>DMSO (vehicle)</p></list-item><list-item><p>1 µM PLX4720</p></list-item><list-item><p>1 µM PLX4720 + 1 µM AZD6244</p></list-item><list-item><p>1 µM PLX4720 + 1 µM CI-1040</p></list-item></list><p>Each condition will be probed with the following antibodies:</p><list list-type="bullet"><list-item><p>pERK1/2 (T202/Y204)</p></list-item><list-item><p>ERK1/2</p></list-item><list-item><p>V5 [additional]</p></list-item><list-item><p>Vinculin</p></list-item><list-item><p>MEK1/2 [additional]</p></list-item><list-item><p>MAP3K8 [additional]</p></list-item></list></sec><sec id="s2-6-2"><title>Materials and reagents</title><p><table-wrap id="tblu8" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent</th><th valign="top">Type</th><th valign="top">Manufacturer</th><th valign="top">Catalog #</th><th valign="top">Comments</th></tr></thead><tbody><tr><td>RPMI medium with L-glutamine</td><td valign="top">Cell culture</td><td>Sigma</td><td>R8758</td><td>Replaces Corning cat no. 10-040-CV.</td></tr><tr><td valign="top">FBS</td><td valign="top">Cell culture</td><td>Life Technologies</td><td>12483-020</td><td>Replaces Corning brand.</td></tr><tr><td valign="top">Pen/strep/glutamine</td><td valign="top">Cell culture</td><td>Abm</td><td>G255</td><td>Replaces Corning brand.</td></tr><tr><td valign="top">A375 cells</td><td valign="top">Cell line</td><td>ATCC</td><td>CRL-1619</td><td>Original brand not specified.</td></tr><tr><td valign="top">PBS</td><td valign="top">Buffer</td><td>Sigma</td><td>D8537-500ML</td><td>Original brand not specified.</td></tr><tr><td valign="top">Trypsin</td><td valign="top">Cell culture</td><td>Sigma</td><td>T4049</td><td>Original brand not specified.</td></tr><tr><td valign="top">10 cm plates</td><td valign="top">Labware</td><td valign="top">CellStar</td><td valign="top">664 160</td><td>Original brand not specified.</td></tr><tr><td valign="top">6 well plates</td><td valign="top">Labware</td><td>Greiner bio-one</td><td>657 160</td><td>Original brand not specified.</td></tr><tr><td valign="top">Polybrene</td><td valign="top">Cell culture</td><td>Sigma</td><td>H9268</td><td>Original brand not specified.</td></tr><tr><td valign="top">Blasticidin</td><td valign="top">Cell culture</td><td>Invivogen</td><td>ant-bl-1</td><td>Original brand not specified.</td></tr><tr><td valign="top">PLX4720</td><td valign="top">Inhibitor</td><td>Selleck Chemicals</td><td>S1152</td><td>Replaces Symansis brand.</td></tr><tr><td valign="top">AZD6244</td><td valign="top">Inhibitor</td><td>Selleck Chemicals</td><td>S1008</td><td>Original catalog # <break/>not specified.</td></tr><tr><td valign="top">CI-1040</td><td valign="top">Inhibitor</td><td>Selleck Chemicals</td><td>S1020</td><td>Replaces Shanghai Lechen International Trading Co. brand.</td></tr><tr><td valign="top">DMSO</td><td valign="top">Chemical</td><td>Sigma</td><td>D4540</td><td>Original brand not specified.</td></tr><tr><td valign="top">NP-40 buffer</td><td valign="top">Buffer</td><td>Life technologies</td><td>FNN0021</td><td>Original brand not specified.</td></tr><tr><td valign="top">Protease inhibitors</td><td valign="top">Inhibitor</td><td>Roche</td><td>04693116001</td><td>Original catalog # <break/>not specified.</td></tr><tr><td valign="top">Phosphatase inhibitor <break/>cocktail I</td><td valign="top">Inhibitor</td><td>Sigma</td><td>P2850</td><td>Replaces CalBioChem brand.</td></tr><tr><td valign="top">Phosphatase inhibitor <break/>cocktail II</td><td valign="top">Inhibitor</td><td>Sigma</td><td>P5726</td><td>Replaces CalBioChem brand.</td></tr><tr><td valign="top">Cell scraper</td><td valign="top">Labware</td><td>Sasrstedt</td><td>83.1830</td><td>Original brand not specified.</td></tr><tr><td valign="top">BCA kit</td><td valign="top">Reporter assay</td><td>Pierce</td><td>23227</td><td>Original catalog # not specified. <break/>Communicated by authors.</td></tr><tr><td valign="top">DTT</td><td valign="top">Chemical</td><td>Biobasic</td><td>DB0058</td><td>Original brand not specified.</td></tr><tr><td valign="top">Sample buffer</td><td valign="top">Buffer</td><td>abm</td><td>G031</td><td>Replaces Invitrogen brand.</td></tr><tr><td valign="top">Protein molecular <break/>weight ladder</td><td valign="top">Western materials</td><td>abm</td><td>G252, G494</td><td>Original brand not specified.</td></tr><tr><td valign="top">10% Tris/Glycine gel; <break/>10 well, 1.0 mm thick</td><td valign="top">Western materials</td><td>abm</td><td>internal</td><td valign="top">Replaces Invitrogen brand.</td></tr><tr><td valign="top">Running buffer</td><td valign="top">Buffer</td><td>abm</td><td>internal</td><td>Original brand not specified.</td></tr><tr><td valign="top">Immobilon P</td><td valign="top">Western materials</td><td>Thermofisher</td><td>IPVH00010</td><td>Original brand not specified.</td></tr><tr><td valign="top">Transfer buffer</td><td valign="top">Buffer</td><td>abm</td><td>internal</td><td>Original brand not specified.</td></tr><tr><td>Mouse anti-pERK1/2 <break/>(T202/Y204) <break/>(clone E10) <break/>antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>9106</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Mouse anti-p44/42 <break/>MAPK (ERK1/2) (clone L34F12) <break/>antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>4696</td><td>Use at 1:11000 dilution. <break/>Replaces catalog # 4695. Communicated by authors.</td></tr><tr><td valign="top">Mouse anti-V5-HRP <break/>conjugated antibody</td><td valign="top">Antibodies</td><td valign="top">Invitrogen</td><td valign="top">R961-25</td><td valign="top">Use at 1:5000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td valign="top">Rabbit anti-Vinculin <break/>antibody</td><td valign="top">Antibodies</td><td valign="top">Sigma</td><td valign="top">V4139</td><td valign="top">Use at 1:20,000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Rabbit anti-MEK1/2 <break/>(clone D1A5) antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>8727</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Rabbit anti-MAP3K8 <break/>(clone M-20) antibody</td><td valign="top">Antibodies</td><td>Santa Cruz</td><td>sc-720</td><td>Use at 1:500 dilution. <break/>Communicated by authors.</td></tr><tr><td>Anti-rabbit IgG – HRP <break/>conjugated antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>7074</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td>Anti-mouse IgG – HRP <break/>conjugated antibody</td><td valign="top">Antibodies</td><td>Cell Signaling</td><td>7076</td><td>Use at 1:1000 dilution. <break/>Original catalog # not specified.</td></tr><tr><td valign="top">Chemiluminescent reagent</td><td valign="top">Western materials</td><td valign="top">Life Technologies</td><td valign="top">WP20005</td><td>Replaces Pierce brand.</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-6-3"><title>Procedure</title><p>Note:</p><list list-type="bullet"><list-item><p>A375 cells maintained in RPMI medium supplemented with 10% FBS and 1% penicillin/streptomycin at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>Cells will be sent for mycoplasma testing and STR profiling.</p></list-item></list><list list-type="order"><list-item><p>Infect A375 cells with viral supernatant:<list list-type="alpha-lower"><list-item><p>Seed 100,000 – 125,000 A375 cells per well in 6 well plates in 2 ml medium. Incubate for 24 hr in normal growth conditions.<list list-type="roman-lower"><list-item><p>Seed six wells per virus. (total wells = 18).</p></list-item></list></p></list-item><list-item><p>Add polybrene (4–10 µg/ml final concentration) to plates, swirl to mix, then infect cells following Protocol 5, step 5 using dilution determined by titration protocol (Protocol 5, step 4).</p></list-item><list-item><p>Incubate for 24 hr, then remove medium and replace with growth medium with or without 10 µg/ml blasticidin.<list list-type="roman-lower"><list-item><p>Five wells without selection and one well with blasticidin for each virus.</p></list-item></list></p></list-item><list-item><p>After 5–7 days of selection, count cells in one well of no-blasticidin and the blasticidin-treated well to calculate infection efficiency.<list list-type="roman-lower"><list-item><p>Divide the counts with blasticidin by the non-selected control.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>72 hr after infection (96 hr after seeding) treat cells with DMSO or 1 µM PLX4720 with or without 1 µM AZD6244, 1 µM CI-1040, or DMSO. Incubate for 24 hr.<list list-type="alpha-lower"><list-item><p>Add drugs directly to each well using a 1000X stock (in DMSO).<list list-type="roman-lower"><list-item><p>Final DMSO concentration kept to 0.2%.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Wash cells with 1–2 ml ice-cold PBS and lyse in 1% NP-40 lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA pH 8, 25 mM NaF, and 1% NP-40) supplemented with 2X protease inhibitors and 1X phosphatase inhibitor cocktails I and II.<list list-type="alpha-lower"><list-item><p>Add ~100–200 µl 1% NP-40 lysis buffer to ensure that protein concentration is between 2–3 µg/µl.</p></list-item><list-item><p>Scrape each plate with a rubber cell scraper, collect lysates, and clarify by centrifugation at max speed (table-top microfuge) at 4˚C.</p></list-item></list></p></list-item><list-item><p>Determine protein concentration by BCA assay, normalize, reduce with DTT, and denature at 88˚C.</p></list-item><list-item><p>Separate 35–50 μg of protein per lane on a 10% Tris/Glycine gel with protein ladder following replicating lab’s standard protocol.<list list-type="alpha-lower"><list-item><p>Samples run per gel(s):<list list-type="roman-lower"><list-item><p>Protein molecular weight marker</p></list-item><list-item><p>Vehicle (DMSO) treated A375 cells expressing MEK1</p></list-item><list-item><p>1 µM PLX4720 treated A375 cells expressing MEK1</p></list-item><list-item><p>1 µM PLX4720 and 1 µM AZD6244 treated A375 cells expressing MEK1</p></list-item><list-item><p>1 µM PLX4720 and 1 µM CI-1040 treated A375 cells expressing MEK1</p></list-item><list-item><p>Vehicle (DMSO) treated A375 cells expressing MEK1<sup>DD</sup></p></list-item><list-item><p>1 µM PLX4720 treated A375 cells expressing MEK1<sup>DD</sup></p></list-item><list-item><p>1 µM PLX4720 and 1 µM AZD6244 treated A375 cells expressing MEK1<sup>DD</sup></p></list-item><list-item><p>1 µM PLX4720 and 1 µM CI-1040 treated A375 cells expressing MEK1<sup>DD</sup></p></list-item><list-item><p>Vehicle (DMSO) treated A375 cells expressing MAP3K8</p></list-item><list-item><p>1 µM PLX4720 treated A375 cells expressing MAP3K8</p></list-item><list-item><p>1 µM PLX4720 and 1 µM AZD6244 treated A375 cells expressing MAP3K8</p></list-item><list-item><p>1 µM PLX4720 and 1 µM CI-1040 treated A375 cells expressing MAP3K8</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Wet transfer with supplied wet-transfer cassette apparatus (120 min at 30–35 V at 4˚C) to immobilon P following replicating lab’s standard protocol.</p></list-item><list-item><p>After transfer, block non-specific binding and immunoblot membrane with the following primary antibodies for 18 hr at 4˚C following manufacturer recommendations:<list list-type="alpha-lower"><list-item><p>mouse anti-pERK1/2 (T202/Y204); use at 1:1000 dilution; 42, 44 kDa</p></list-item><list-item><p>mouse anti-ERK1/2; use at 1:1000 dilution; 42, 44 kDa</p></list-item><list-item><p>mouse anti-V5-HRP; use at 1:5000 dilution; 45 kDa for MEK1, 52, 58 kDa for MAP3K8</p></list-item><list-item><p>rabbit anti-Vinculin; use at 1:20,000 dilution; 116 kDa</p></list-item><list-item><p>rabbit anti-MAP3K8; use at 1:500 dilution; 52, 58 kDa</p></list-item><list-item><p>rabbit anti-MEK1/2; use at 1:1000 dilution; 45 kDa</p></list-item></list><table-wrap id="tblu9" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="5"><p>Protocol 6 Western blot antibody combinations</p></th></tr><tr><th/><th colspan="2">POI</th><th colspan="2">Loading control</th></tr><tr><th>Independent Gels</th><th>Description</th><th>Working Conc.</th><th>Description</th><th>Working Conc.</th></tr></thead><tbody><tr><td>1</td><td>Mouse anti-pERK1/2 <break/>(T202/Y204) (42, 44 kDa)</td><td>1:1000</td><td>Rabbit anti-MEK1/2 <break/>(45 kDa)</td><td>1:1000</td></tr><tr><td>2</td><td>Mouse anti-V5-HRP <break/>(45, 52, 58 kDa)</td><td>1:5000</td><td>Rabbit anti-Vinculin (116 kDa)</td><td>1:20000</td></tr><tr><td>3</td><td>Rabbit anti-MAP3K8 <break/>(52, 58 kDa)</td><td>1:500</td><td>Mouse anti-ERK1/2 <break/>(42, 44 kDa)</td><td>1:1000</td></tr></tbody></table></table-wrap></p></list-item><list-item><p>Apply appropriate HRP-linked secondary antibodies for 1 hr at RT with constant agitation, and then detect signal using chemiluminescence following manufacturer’s instructions.<list list-type="alpha-lower"><list-item><p>Note: If a Li-COR Odyssey imaging system is available for use, IR Dye-labeled secondary antibodies and a low fluorescence membrane will be used instead, and images will be acquired following manufacturer’s instructions.</p></list-item></list></p></list-item><list-item><p>Analyze bands with image analysis software and normalize to loading controls.<list list-type="alpha-lower"><list-item><p>pERK1/2 (T202/Y204) normalized to MEK1/2 (total).</p></list-item><list-item><p>V5 (tag on exogenous proteins) normalized to Vinculin.</p></list-item></list></p></list-item><list-item><p>Repeat steps 1–9 independently two additional times.</p></list-item></list></sec><sec id="s2-6-4"><title>Deliverables:</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Raw counts and infection efficiency (step 1 above).</p></list-item><list-item><p>Full image western blot films of all immunoblots including ladder. (Compare to Figures 2A and 4F.)</p></list-item><list-item><p>Raw data of band analysis and normalized bands for each sample.</p></list-item></list></p></list-item></list></sec><sec id="s2-6-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data:<list list-type="bullet"><list-item><p>One-way ANOVA of normalized pERK1/2 levels of A375 cells expressing MAP3K8 treated with vehicle, PLX4720, PLX4720 + CI-1040, or PLX4720 + AZD6244 with the following planned comparisons using the Bonferroni correction:<list list-type="bullet"><list-item><p>PLX4720 treatment compared to PLX4720 + CI-1040.</p></list-item><list-item><p>PLX4720 treatment compared to PLX4720 + AZD6244.</p></list-item></list></p></list-item><list-item><p>Two-way ANOVA of normalized pERK1/2 levels of A375 cells expressing MEK1 or MEK1<sup>DD</sup> treated with vehicle, PLX4720, PLX4720 + CI-1040, or PLX4720 + AZD6244.</p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>The replication data (mean and 95% confidence interval) will be plotted with the original reported data value plotted as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></sec><sec id="s2-6-6"><title>Known differences from the original study</title><p>The original NP40 cell lysis buffer was composed of: 150 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA pH 8, 25 mM NaF, and 1% NP-40. The replication will use a commercial formula, which has the following composition: 250 mM NaCl, 50 mM Tris pH 7.4, 5 mM EDTA, 50 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, and 1% NP-40. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-6-7"><title>Provisions for quality control</title><p>The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. Infection efficiency will be determined for each replicate. The expression of the kinase of interest will be assessed using antibodies against the V5 tag as well as MAP3K8 and MEK1. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/lmhjg/">https://osf.io/lmhjg/</ext-link>) and made publically available.</p></sec><sec id="s2-6-8"><title>Power Calculations</title><p>For additional details on power calculations, please see analysis scripts and associated files on the Open Science Framework:</p><p><ext-link ext-link-type="uri" xlink:href="https://osf.io/sptzv/">https://osf.io/sptzv/</ext-link></p></sec></sec><sec id="s2-7"><title>Protocol 1</title><p>The original data presented is qualitative (images of Western blots). We used Image Studio Lite v. 4.0.21 (LI-COR) to perform densitometric analysis of the presented bands to quantify the original effect size where possible. To identify a suitable sample size, power calculations were performed using different levels of relative variance.</p><sec id="s2-7-1"><title>Summary of estimated original data reported in Figure 3E:</title><p><table-wrap id="tblu10" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Cell line</th><th valign="top">PLX4720 concentration (µM)</th><th valign="top">Normalized pMEK/ERK</th><th valign="top">Normalized pERK/MEK</th></tr></thead><tbody><tr><td rowspan="4" valign="top">A375</td><td valign="top">0 (DMSO)</td><td valign="top">1.000</td><td valign="top">1.000</td></tr><tr><td valign="top">10</td><td valign="top">0.00212</td><td valign="top">0.0147</td></tr><tr><td valign="top">1</td><td valign="top">0.00283</td><td valign="top">0.0254</td></tr><tr><td valign="top">0.1</td><td valign="top">0.0981</td><td valign="top">0.00283</td></tr><tr><td rowspan="4" valign="top">RPMI-7951</td><td valign="top">0 (DMSO)</td><td valign="top">1.000</td><td valign="top">1.000</td></tr><tr><td valign="top">10</td><td valign="top">0.827</td><td valign="top">1.849</td></tr><tr><td valign="top">1</td><td valign="top">0.380</td><td valign="top">1.460</td></tr><tr><td valign="top">0.1</td><td valign="top">0.471</td><td valign="top">1.022</td></tr><tr><td rowspan="4" valign="top">OUMS-23</td><td valign="top">0 (DMSO)</td><td valign="top">1.000</td><td valign="top">1.000</td></tr><tr><td valign="top">10</td><td valign="top">0.0579</td><td valign="top">0.926</td></tr><tr><td valign="top">1</td><td valign="top">0.197</td><td valign="top">1.042</td></tr><tr><td valign="top">0.1</td><td valign="top">1.100</td><td valign="top">1.068</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-7-2"><title>Test family</title><list list-type="bullet"><list-item><p><italic>F</italic> test, ANOVA: Fixed effects, special, main effects and interactions, Bonferorni’s correction: alpha error = 0.00833</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p><p>Partial η<sup>2</sup> calculated from (<xref ref-type="bibr" rid="bib11">Lakens, 2013</xref>).</p><p>Comparisons are between DMSO and all PLX4720 doses (10, 1, and 0.1 µM)</p><p><table-wrap id="tblu11" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibody</th><th valign="top">Cell line</th><th valign="top">F test statistic</th><th valign="top">Partial η<sup>2</sup></th><th valign="top">Effect size <italic>f</italic></th><th valign="top">A priori power</th><th valign="top">Total sample size</th></tr></thead><tbody><tr><td colspan="7" valign="top">2% variance</td></tr><tr><td rowspan="3" valign="top">pMEK</td><td valign="top">A375</td><td valign="top">F(1,8) = 20781</td><td valign="top">0.99962</td><td valign="top">50.9670</td><td valign="top">99.9%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">RPMI-7951</td><td valign="top">F(1,8) = 2128.4</td><td valign="top">0.99626</td><td valign="top">16.3112<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">OUMS-23</td><td valign="top">F(1,8) = 3001.0</td><td valign="top">0.99734</td><td valign="top">19.3683<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td rowspan="3" valign="top">pERK</td><td valign="top">A375</td><td valign="top">F(1,8) = 21841</td><td valign="top">0.99963</td><td valign="top">52.2504</td><td valign="top">99.9%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">RPMI-7951</td><td valign="top">F(1,8) = 582.85</td><td valign="top">0.98646</td><td valign="top">8.53562<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">OUMS-23</td><td valign="top">F(1,8) = 0.8080</td><td valign="top">0.09173</td><td valign="top">0.31780<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td colspan="7" valign="top">15% variance</td></tr><tr><td rowspan="3" valign="top">pMEK</td><td valign="top">A375</td><td valign="top">F(1,8) = 369.44</td><td valign="top">0.97880</td><td valign="top">6.79560</td><td valign="top">99.9%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">RPMI-7951</td><td valign="top">F(1,8) = 37.839</td><td valign="top">0.82547</td><td valign="top">2.17482<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">OUMS-23</td><td valign="top">F(1,8) = 53.352</td><td valign="top">0.86960</td><td valign="top">2.58244<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td rowspan="3" valign="top">pERK</td><td valign="top">A375</td><td valign="top">F(1,8) = 388.28</td><td valign="top">0.97981</td><td valign="top">6.96672</td><td valign="top">99.9%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">RPMI-7951</td><td valign="top">F(1,8) = 10.362</td><td valign="top">0.56431</td><td valign="top">1.13808<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">OUMS-23</td><td valign="top">F(1,8) = 0.01436</td><td valign="top">0.001792</td><td valign="top">0.04237<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td colspan="7" valign="top">28% variance</td></tr><tr><td rowspan="3" valign="top">pMEK</td><td valign="top">A375</td><td valign="top">F(1,8) = 106.68</td><td valign="top">0.92984</td><td valign="top">3.64050</td><td valign="top">99.9%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">RPMI-7951</td><td valign="top">F(1,8) = 10.859</td><td valign="top">0.57581</td><td valign="top">1.16509<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">OUMS-23</td><td valign="top">F(1,8) = 15.312</td><td valign="top">0.65682</td><td valign="top">1.38345<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td rowspan="3" valign="top">pERK</td><td valign="top">A375</td><td valign="top">F(1,8) = 111.43</td><td valign="top">0.93302</td><td valign="top">3.73217</td><td valign="top">99.9%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">RPMI-7951</td><td valign="top">F(1,8) = 2.9737</td><td valign="top">0.27099</td><td valign="top">0.60969<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">OUMS-23</td><td valign="top">F(1,8) = 0.04122</td><td valign="top">0.000515</td><td valign="top">0.02270<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td colspan="7" valign="top">40% variance</td></tr><tr><td rowspan="3" valign="top">pMEK</td><td valign="top">A375</td><td valign="top">F(1,8) = 51.952</td><td valign="top">0.86656</td><td valign="top">2.54835</td><td valign="top">99.9%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">RPMI-7951</td><td valign="top">F(1,8) = 5.3211</td><td valign="top">0.39945</td><td valign="top">0.81556<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">OUMS-23</td><td valign="top">F(1,8) = 7.5026</td><td valign="top">0.48396</td><td valign="top">0.96842<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td rowspan="3" valign="top">pERK</td><td valign="top">A375</td><td valign="top">F(1,8) = 54.602</td><td valign="top">0.87221</td><td valign="top">2.61252</td><td valign="top">99.9%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">RPMI-7951</td><td valign="top">F(1,8) = 1.4571</td><td valign="top">0.15408</td><td valign="top">0.42678<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">OUMS-23</td><td valign="top">F(1,8) = 0.00202</td><td valign="top">0.000252</td><td valign="top">0.01589<sup>1</sup></td><td valign="top">80.0%</td><td valign="top">12 <break/>(4 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p><sup>1</sup> This is the calculated effect size using the originally reported value with the indicated variance. Unlike the power calculations to determine sample size, the aim of these sensitivity calculations are not to detect the original effect size, but to understand what effect size could be detected with 80% power and the indicated total sample size of 12. The detectable effect size is 1.29189.</p></fn></table-wrap-foot></table-wrap></p><p>In order to produce quantitative replication data, we will run the experiment three times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p></sec></sec><sec id="s2-8"><title>Protocol 2</title><p>Not applicable</p></sec><sec id="s2-9"><title>Protocol 3</title><p>The original data is from a single biological replicate. To identify a suitable sample size, power calculations were performed using different levels of relative variance.</p><sec id="s2-9-1"><title>Summary of estimated original data reported in Figure 3D:</title><p><table-wrap id="tblu12" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Cell line</th><th valign="top">GI<sub>50</sub> (µM)</th></tr></thead><tbody><tr><td valign="top">A375</td><td valign="top">0.2276</td></tr><tr><td valign="top">RPMI-7951</td><td valign="top">10.862</td></tr><tr><td valign="top">OUMS-23</td><td valign="top">8.731</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-9-2"><title>Test family</title><list list-type="bullet"><list-item><p>2 tailed <italic>t</italic> test, difference between two independent means, Fisher’s LSD: alpha error = 0.05</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p><p><table-wrap id="tblu13" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Group 1</th><th valign="top">Group 2</th><th valign="top">Effect size <italic>d</italic></th><th valign="top">A priori power</th><th valign="top">Group 1 sample size</th><th valign="top">Group 2 sample size</th></tr></thead><tbody><tr><td colspan="6" valign="top">2% variance</td></tr><tr><td valign="top">A375</td><td valign="top">RPMI-7951</td><td valign="top">69.2139</td><td valign="top">99.9%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td valign="top">A375</td><td valign="top">OUMS-23</td><td valign="top">55.3442</td><td valign="top">99.9%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td colspan="6" valign="top">15% variance</td></tr><tr><td valign="top">A375</td><td valign="top">RPMI-7951</td><td valign="top">68.3898</td><td valign="top">99.9%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td valign="top">A375</td><td valign="top">OUMS-23</td><td valign="top">7.37923</td><td valign="top">93.3%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td colspan="6" valign="top">28% variance</td></tr><tr><td valign="top">A375</td><td valign="top">RPMI-7951</td><td valign="top">4.94385</td><td valign="top">99.2%</td><td valign="top">3</td><td valign="top">3</td></tr><tr><td valign="top">A375</td><td valign="top">OUMS-23</td><td valign="top">3.95316</td><td valign="top">94.4%</td><td valign="top">3</td><td valign="top">3</td></tr><tr><td colspan="6" valign="top">40% variance</td></tr><tr><td valign="top">A375</td><td valign="top">RPMI-7951</td><td valign="top">3.46070</td><td valign="top">88.0%</td><td valign="top">3</td><td valign="top">3</td></tr><tr><td valign="top">A375</td><td valign="top">OUMS-23</td><td valign="top">2.76721</td><td valign="top">90.0%</td><td valign="top">4</td><td valign="top">4</td></tr></tbody></table></table-wrap></p><p>In order to produce quantitative replication data, we will run the experiment three times. Each time we will calculate the GI<sub>50</sub> value. We will determine the standard deviation of GI<sub>50</sub> values across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p></sec></sec><sec id="s2-10"><title>Protocol 4</title><p>The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.</p><sec id="s2-10-1"><title>Summary of original data reported in Figure 3I:</title><p><table-wrap id="tblu14" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Cell line</th><th valign="top">MAP3K8 inhibitor concentration (µM)</th><th valign="top">Normalized pMEK/ERK</th><th valign="top">Normalized pERK/MEK</th></tr></thead><tbody><tr><td rowspan="5" valign="top">RPMI-7951</td><td valign="top">0 (DMSO)</td><td valign="top">1.00</td><td valign="top">1.00</td></tr><tr><td valign="top">1</td><td valign="top">1.35</td><td valign="top">1.00</td></tr><tr><td valign="top">5</td><td valign="top">1.15</td><td valign="top">0.92</td></tr><tr><td valign="top">10</td><td valign="top">0.70</td><td valign="top">0.75</td></tr><tr><td valign="top">20</td><td valign="top">0.36</td><td valign="top">0.71</td></tr></tbody></table></table-wrap></p><p>IC<sub>50</sub> values performed with R software, version 3.2.1 (<xref ref-type="bibr" rid="bib23">Team, 2015</xref>).</p><p><table-wrap id="tblu15" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">IC<sub>50</sub> value of normalized pMEK values</th><th valign="top">IC<sub>50</sub> value of normalized pERK values</th></tr></thead><tbody><tr><td valign="top">9.4725</td><td valign="top">6.4091</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-10-2"><title>Test family</title><list list-type="bullet"><list-item><p><italic>F</italic> test, ANOVA: Fixed effects, omnibus, one-way, Bonferroni’s correction: alpha error = 0.025</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p><p>ANOVA F test statistic and partial η<sup>2 </sup>performed with R software, version 3.2.1 (<xref ref-type="bibr" rid="bib23">Team, 2015</xref>).</p><p>Partial η<sup>2</sup> calculated from (<xref ref-type="bibr" rid="bib11">Lakens, 2013</xref>).</p><p><table-wrap id="tblu16" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Groups</th><th valign="top">Antibody</th><th valign="top">F test statistic</th><th valign="top">Partial η<sup>2</sup></th><th valign="top">Effect size <italic>f</italic></th><th valign="top">A priori power</th><th valign="top">Total sample size</th></tr></thead><tbody><tr><td colspan="7" valign="top">2% variance</td></tr><tr><td rowspan="2" valign="top">MAP3K8 inhibitor (1, 5, 10, 20 µM)</td><td valign="top">pMEK</td><td valign="top">F(3,8) = 1583.7</td><td valign="top">0.99832</td><td valign="top">24.3697</td><td valign="top">99.9%</td><td valign="top">8 <break/>(4 groups)</td></tr><tr><td valign="top">pERK</td><td valign="top">F(3,8) = 195.33</td><td valign="top">0.98653</td><td valign="top">8.55863</td><td valign="top">99.9%</td><td valign="top">8 <break/>(4 groups)</td></tr><tr><td colspan="7" valign="top">15% variance</td></tr><tr><td rowspan="2" valign="top">MAP3K8 inhibitor (1, 5, 10, 20 µM)</td><td valign="top">pMEK</td><td valign="top">F(3,8) = 28.155</td><td valign="top">0.91348</td><td valign="top">3.24931</td><td valign="top">96.8%</td><td valign="top">8 <break/>(4 groups)</td></tr><tr><td valign="top">pERK</td><td valign="top">F(3,8) = 3.4726</td><td valign="top">0.56563</td><td valign="top">1.14114</td><td valign="top">83.6%</td><td valign="top">16 <break/>(4 groups)</td></tr><tr><td colspan="7" valign="top">28% variance</td></tr><tr><td rowspan="2" valign="top">MAP3K8 inhibitor (1, 5, 10, 20 µM)</td><td valign="top">pMEK</td><td valign="top">F(3,8) = 8.0801</td><td valign="top">0.75186</td><td valign="top">1.74070</td><td valign="top">94.7%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td valign="top">pERK</td><td valign="top">F(3,8) = 0.9966</td><td valign="top">0.27205</td><td valign="top">0.61133</td><td valign="top">80.8%</td><td valign="top">40 <break/>(4 groups)</td></tr><tr><td colspan="7" valign="top">40% variance</td></tr><tr><td rowspan="2" valign="top">MAP3K8 inhibitor (1, 5, 10, 20 µM)</td><td valign="top">pMEK</td><td valign="top">F(3,8) = 3.9593</td><td valign="top">0.59754</td><td valign="top">1.21849</td><td valign="top">88.7%</td><td valign="top">16 <break/>(4 groups)</td></tr><tr><td valign="top">pERK</td><td valign="top">F(3,8) = 0.4883</td><td valign="top">0.15478</td><td valign="top">0.42793</td><td valign="top">80.5%</td><td valign="top">76 <break/>(4 groups)</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-10-3"><title>Test family</title><list list-type="bullet"><list-item><p><italic>t</italic>-test: Means: Difference from constant (one sample case): Bonferroni’s correction: alpha error = 0.025</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p><p><table-wrap id="tblu17" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">MAP3K8 inhibitor dose</th><th valign="top">Constant (vehicle)</th><th valign="top">Antibody</th><th valign="top">Effect size <italic>d</italic></th><th valign="top">A priori power</th><th valign="top">Sample size <break/>per group</th></tr></thead><tbody><tr><td colspan="6" valign="top">2% variance</td></tr><tr><td rowspan="2" valign="top">20 µM</td><td rowspan="2" valign="top">0 µM</td><td valign="top">pMEK</td><td valign="top">88.8889</td><td valign="top">99.9%</td><td valign="top">3</td></tr><tr><td valign="top">pERK</td><td valign="top">20.4225</td><td valign="top">99.9%</td><td valign="top">3</td></tr><tr><td colspan="6" valign="top">15% variance</td></tr><tr><td rowspan="2" valign="top">20 µM</td><td rowspan="2" valign="top">0 µM</td><td valign="top">pMEK</td><td valign="top">11.8519</td><td valign="top">99.9%</td><td valign="top">3</td></tr><tr><td valign="top">pERK</td><td valign="top">2.72300</td><td valign="top">80.2%</td><td valign="top">4</td></tr><tr><td colspan="6" valign="top">28% variance</td></tr><tr><td rowspan="2" valign="top">20 µM</td><td rowspan="2" valign="top">0 µM</td><td valign="top">pMEK</td><td valign="top">6.34921</td><td valign="top">95.1%</td><td valign="top">3</td></tr><tr><td valign="top">pERK</td><td valign="top">1.45875</td><td valign="top">86.6%</td><td valign="top">8</td></tr><tr><td colspan="6" valign="top">40% variance</td></tr><tr><td rowspan="2" valign="top">20 µM</td><td rowspan="2" valign="top">0 µM</td><td valign="top">pMEK</td><td valign="top">4.44444</td><td valign="top">99.2%</td><td valign="top">4</td></tr><tr><td valign="top">pERK</td><td valign="top">1.02113</td><td valign="top">81.1%</td><td valign="top">12</td></tr></tbody></table></table-wrap></p><p>In order to produce quantitative replication data, we will run the experiment eight times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p></sec></sec><sec id="s2-11"><title>Protocol 5</title><p>The original data is from a single biological replicate. To identify a suitable sample size, power calculations were performed using different levels of relative variance.</p><sec id="s2-11-1"><title>Summary of original data reported in Figure 4E (provided by authors)</title><p><table-wrap id="tblu18" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Cell line</th><th valign="top">Drug(s)</th><th valign="top">Relative viability</th><th valign="top">Technical replicate stdev</th></tr></thead><tbody><tr><td rowspan="5" valign="top">MEK1</td><td valign="top">DMSO</td><td valign="top">100</td><td valign="top">5.09</td></tr><tr><td valign="top">PLX4720 (10 µM)</td><td valign="top">5.78</td><td valign="top">0.67</td></tr><tr><td valign="top">PLX4720 (1 µM)</td><td valign="top">11.32</td><td valign="top">0.97</td></tr><tr><td valign="top">PLX4720 (1 µM) + CI-1040 (1 µM)</td><td valign="top">10.13</td><td valign="top">0.60</td></tr><tr><td valign="top">PLX4720 (1 µM) + AZD6244 (1 µM)</td><td valign="top">10.92</td><td valign="top">0.91</td></tr><tr><td rowspan="5" valign="top">MEK1<sup>DD</sup></td><td valign="top">DMSO</td><td valign="top">96.96</td><td valign="top">9.40</td></tr><tr><td valign="top">PLX4720 (10 µM)</td><td valign="top">97.56</td><td valign="top">6.25</td></tr><tr><td valign="top">PLX4720 (1 µM)</td><td valign="top">92.10</td><td valign="top">8.23</td></tr><tr><td valign="top">PLX4720 (1 µM) + CI-1040 (1 µM)</td><td valign="top">102.24</td><td valign="top">8.55</td></tr><tr><td valign="top">PLX4720 (1 µM) + AZD6244 (1 µM)</td><td valign="top">42.44</td><td valign="top">2.74</td></tr><tr><td rowspan="5" valign="top">MAP3K8</td><td valign="top">DMSO</td><td valign="top">100</td><td valign="top">10.66</td></tr><tr><td valign="top">PLX4720 (10 µM)</td><td valign="top">43.44</td><td valign="top">3.48</td></tr><tr><td valign="top">PLX4720 (1 µM)</td><td valign="top">62.81</td><td valign="top">5.05</td></tr><tr><td valign="top">PLX4720 (1 µM) + CI-1040 (1 µM)</td><td valign="top">13.42</td><td valign="top">2.42</td></tr><tr><td valign="top">PLX4720 (1 µM) + AZD6244 (1 µM)</td><td valign="top">12.52</td><td valign="top">1.65</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-11-2"><title>Test family</title><list list-type="bullet"><list-item><p><italic>F</italic> test, ANOVA: Fixed effects, omnibus, one-way, alpha error = 0.05.</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p><p>ANOVA F test statistic and partial η<sup>2 </sup>performed with R software, version 3.2.1 (<xref ref-type="bibr" rid="bib23">Team, 2015</xref>).</p></sec><sec id="s2-11-3"><title>MAP3K8 values</title><p><table-wrap id="tblu19" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Groups</th><th valign="top">F test statistic</th><th valign="top">Partial η<sup>2</sup></th><th valign="top">Effect size <italic>f</italic></th><th valign="top">A priori power</th><th valign="top">Total sample size</th></tr></thead><tbody><tr><td colspan="6" valign="top">2% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(4,25) = 6246.6</td><td valign="top">0.99900</td><td valign="top">31.60696</td><td valign="top">99.9%</td><td valign="top">10 <break/>(5 groups)</td></tr><tr><td colspan="6" valign="top">15% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(4,25) = 111.04</td><td valign="top">0.94672</td><td valign="top">4.21509</td><td valign="top">99.9%</td><td valign="top">15 <break/>(5 groups)</td></tr><tr><td colspan="6" valign="top">28% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(4,25) = 31.868</td><td valign="top">0.83604</td><td valign="top">2.25807</td><td valign="top">99.9%</td><td valign="top">20 <break/>(5 groups)</td></tr><tr><td colspan="6" valign="top">40% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(4,25) = 15.615</td><td valign="top">0.71416</td><td valign="top">1.58066</td><td valign="top">99.9%</td><td valign="top">25 <break/>(5 groups)</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-11-4"><title>Test family</title><list list-type="bullet"><list-item><p>2 tailed <italic>t</italic> test, difference between two independent means, Bonferroni’s correction: alpha error = 0.0125</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p></sec><sec id="s2-11-5"><title>MAP3K8 values</title><p><table-wrap id="tblu20" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Group 1</th><th valign="top">Group 2</th><th valign="top">Effect size <italic>d</italic></th><th valign="top">A priori power</th><th valign="top">Group 1 sample size</th><th valign="top">Group 2 sample size</th></tr></thead><tbody><tr><td colspan="6" valign="top">2% variance</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">67.45484</td><td valign="top">99.9%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">55.51810</td><td valign="top">99.9%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td valign="top">10 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">46.68351</td><td valign="top">99.9%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td valign="top">10 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">48.35265</td><td valign="top">99.9%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td colspan="6" valign="top">15% variance</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">7.24974</td><td valign="top">99.4%</td><td valign="top">3</td><td valign="top">3</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">7.40241</td><td valign="top">99.6%</td><td valign="top">3</td><td valign="top">3</td></tr><tr><td valign="top">10 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">6.22447</td><td valign="top">97.2%</td><td valign="top">3</td><td valign="top">3</td></tr><tr><td valign="top">10 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">6.44702</td><td valign="top">97.9%</td><td valign="top">3</td><td valign="top">3</td></tr><tr><td colspan="6" valign="top">28% variance</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">3.88379</td><td valign="top">93.0%</td><td valign="top">4</td><td valign="top">4</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">3.96558</td><td valign="top">94.0%</td><td valign="top">4</td><td valign="top">4</td></tr><tr><td valign="top">10 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">3.33454</td><td valign="top">82.9%</td><td valign="top">4</td><td valign="top">4</td></tr><tr><td valign="top">10 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">3.45376</td><td valign="top">85.7%</td><td valign="top">4</td><td valign="top">4</td></tr><tr><td colspan="6" valign="top">40% variance</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">2.71865</td><td valign="top">82.6%</td><td valign="top">5</td><td valign="top">5</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">2.77591</td><td valign="top">84.3%</td><td valign="top">5</td><td valign="top">5</td></tr><tr><td valign="top">10 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">2.33418</td><td valign="top">81.5%</td><td valign="top">6</td><td valign="top">6</td></tr><tr><td valign="top">10 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">2.41763</td><td valign="top">84.5%</td><td valign="top">6</td><td valign="top">6</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-11-6"><title>Test family</title><list list-type="bullet"><list-item><p><italic>F</italic> test, ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05.</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p><p>ANOVA F test statistic and partial η<sup>2 </sup>performed with R software, version 3.2.1 (<xref ref-type="bibr" rid="bib23">Team, 2015</xref>).</p></sec><sec id="s2-11-7"><title>MEK1 and MEK1<sup>DD</sup> values</title><p><table-wrap id="tblu21" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Groups</th><th valign="top">F test statistic</th><th valign="top">Partial η<sup>2</sup></th><th valign="top">Effect size <italic>f</italic></th><th valign="top">A priori power</th><th valign="top">Total sample size</th></tr></thead><tbody><tr><td colspan="6" valign="top">2% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(4,50) = 2716.2</td><td valign="top">0.99542</td><td valign="top">14.7409</td><td valign="top">99.9%</td><td valign="top">20 <break/>(10 groups)</td></tr><tr><td colspan="6" valign="top">15% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(4,50) = 48.287</td><td valign="top">0.79437</td><td valign="top">1.96545</td><td valign="top">99.9%</td><td valign="top">30 <break/>(10 groups)</td></tr><tr><td colspan="6" valign="top">28% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(4,50) = 13.858</td><td valign="top">0.52576</td><td valign="top">1.05292</td><td valign="top">99.9%</td><td valign="top">40 <break/>(10 groups)</td></tr><tr><td colspan="6" valign="top">40% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(4,50) = 6.7904</td><td valign="top">0.35201</td><td valign="top">0.73704</td><td valign="top">98.7%</td><td valign="top">50 <break/>(10 groups)</td></tr></tbody></table></table-wrap></p><p>In order to produce quantitative replication data, we will run the experiment four times. Each time we will quantify relative viability. We will determine the standard deviation of viability values across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p></sec></sec><sec id="s2-12"><title>Protocol 6</title><p>The original data presented is qualitative (images of Western blots). We used Image Studio Lite v. 4.0.21 (LI-COR) to perform densitometric analysis of the presented bands to quantify the original effect size where possible.</p><p>Summary of estimated original data reported in Figure 4F:</p><p><table-wrap id="tblu22" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Cell line</th><th valign="top">Drug(s)</th><th valign="top">Normalized pERK/ERK</th></tr></thead><tbody><tr><td rowspan="4" valign="top">MEK1</td><td valign="top">DMSO</td><td valign="top">1.0000</td></tr><tr><td valign="top">PLX4720 (1 µM)</td><td valign="top">0.0799</td></tr><tr><td valign="top">PLX4720 (1 µM) + CI-1040 (1 µM)</td><td valign="top">0.0021</td></tr><tr><td valign="top">PLX4720 (1 µM) + AZD6244 (1 µM)</td><td valign="top">0.0002</td></tr><tr><td rowspan="4" valign="top">MEK1<sup>DD</sup></td><td valign="top">DMSO</td><td valign="top">1.0000</td></tr><tr><td valign="top">PLX4720 (1 µM)</td><td valign="top">1.0203</td></tr><tr><td valign="top">PLX4720 (1 µM) + CI-1040 (1 µM)</td><td valign="top">0.3015</td></tr><tr><td valign="top">PLX4720 (1 µM) + AZD6244 (1 µM)</td><td valign="top">0.0166</td></tr><tr><td rowspan="4" valign="top">MAP3K8</td><td valign="top">DMSO</td><td valign="top">1.0000</td></tr><tr><td valign="top">PLX4720 (1 µM)</td><td valign="top">0.7689</td></tr><tr><td valign="top">PLX4720 (1 µM) + CI-1040 (1 µM)</td><td valign="top">0.0045</td></tr><tr><td valign="top">PLX4720 (1 µM) + AZD6244 (1 µM)</td><td valign="top">0.0063</td></tr></tbody></table></table-wrap></p><sec id="s2-12-1"><title>Test family</title><list list-type="bullet"><list-item><p><italic>F</italic> test, ANOVA: Fixed effects, omnibus, one-way, alpha error = 0.05.</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p><p>ANOVA F test statistic and partial η<sup>2 </sup>performed with R software, version 3.2.1 (<xref ref-type="bibr" rid="bib23">Team, 2015</xref>).</p></sec><sec id="s2-12-2"><title>MAP3K8 values</title><p><table-wrap id="tblu23" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Groups</th><th valign="top">F test statistic</th><th valign="top">Partial η<sup>2</sup></th><th valign="top">Effect size <italic>f</italic></th><th valign="top">A priori power</th><th valign="top">Total sample size</th></tr></thead><tbody><tr><td colspan="6" valign="top">2% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(3,8) = 5024.1</td><td valign="top">0.99947</td><td valign="top">43.4257</td><td valign="top">99.9%</td><td valign="top">8 <break/>(4 groups)</td></tr><tr><td colspan="6" valign="top">15% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(3,8) = 89.317</td><td valign="top">0.97101</td><td valign="top">5.78735</td><td valign="top">99.9%</td><td valign="top">8 <break/>(4 groups)</td></tr><tr><td colspan="6" valign="top">28% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(3,8) = 25.633</td><td valign="top">0.90577</td><td valign="top">3.10038</td><td valign="top">99.9%</td><td valign="top">12 <break/>(4 groups)</td></tr><tr><td colspan="6" valign="top">40% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(3,8) = 12.560</td><td valign="top">0.82487</td><td valign="top">2.17026</td><td valign="top">99.9%</td><td valign="top">16 <break/>(4 groups)</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-12-3"><title>Test family</title><list list-type="bullet"><list-item><p>2 tailed <italic>t</italic> test, difference between two independent means, Bonferroni’s correction: alpha error = 0.025</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p></sec><sec id="s2-12-4"><title>MAP3K8 values</title><p><table-wrap id="tblu24" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Group 1</th><th valign="top">Group 2</th><th valign="top">Effect size <italic>d</italic></th><th valign="top">A priori power</th><th valign="top">Group 1 sample size</th><th valign="top">Group 2 sample size</th></tr></thead><tbody><tr><td colspan="6" valign="top">2% variance</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">68.8057</td><td valign="top">99.9%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">70.5269</td><td valign="top">99.9%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td colspan="6" valign="top">15% variance</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">9.17409</td><td valign="top">87.8%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">9.40358</td><td valign="top">89.0%</td><td valign="top">2</td><td valign="top">2</td></tr><tr><td colspan="6" valign="top">28% variance</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">4.91469</td><td valign="top">95.5%</td><td valign="top">3</td><td valign="top">3</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">5.03763</td><td valign="top">96.3%</td><td valign="top">3</td><td valign="top">3</td></tr><tr><td colspan="6" valign="top">40% variance</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM CI1040</td><td valign="top">3.44028</td><td valign="top">93.7%</td><td valign="top">4</td><td valign="top">4</td></tr><tr><td valign="top">1 µM PLX4720</td><td valign="top">1 µM PLX4720 + 1 µM AZD6244</td><td valign="top">3.52634</td><td valign="top">94.7%</td><td valign="top">4</td><td valign="top">4</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-12-5"><title>Test family</title><list list-type="bullet"><list-item><p><italic>F</italic> test, ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05.</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p><p>ANOVA F test statistic and partial η<sup>2 </sup>performed with R software, version 3.2.1 (<xref ref-type="bibr" rid="bib23">Team, 2015</xref>).</p></sec><sec id="s2-12-6"><title>MEK1 and MEK1<sup>DD</sup> values</title><p><table-wrap id="tblu25" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Groups</th><th valign="top">F test statistic</th><th valign="top">Partial η<sup>2</sup></th><th valign="top">Effect size <italic>f</italic></th><th valign="top">A priori power</th><th valign="top">Total sample size</th></tr></thead><tbody><tr><td colspan="6" valign="top">2% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(3,16) = 1847.2</td><td valign="top">0.99712</td><td valign="top">18.6103</td><td valign="top">99.9%</td><td valign="top">16 <break/>(8 groups)</td></tr><tr><td colspan="6" valign="top">15% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(3,16) = 32.840</td><td valign="top">0.86029</td><td valign="top">2.48143</td><td valign="top">99.9%</td><td valign="top">16 <break/>(8 groups)</td></tr><tr><td colspan="6" valign="top">28% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(3,16) = 9.4247</td><td valign="top">0.63862</td><td valign="top">1.32934</td><td valign="top">99.9%</td><td valign="top">24 <break/>(8 groups)</td></tr><tr><td colspan="6" valign="top">40% variance</td></tr><tr><td valign="top">All treatments</td><td valign="top">F(3,16) = 4.6181</td><td valign="top">0.46406</td><td valign="top">0.93053</td><td valign="top">99.0%</td><td valign="top">32 <break/>(8 groups)</td></tr></tbody></table></table-wrap></p><p>In order to produce quantitative replication data, we will run the experiment three times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The Reproducibility Project: Cancer Biology core team would like to thank the original authors, in particular Cory Johannessen, for generously sharing critical information as well as reagents to ensure the fidelity and quality of this replication attempt. We thank Courtney Soderberg at the Center for Open Science for assistance with statistical analyses. We would also like to thank the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology; American Type Culture Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma-Aldrich, and System Biosciences (SBI).</p></ack><sec id="s3" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>VS: Applied Biological Materials is a Science Exchange associated laboratory.</p></fn><fn fn-type="conflict" id="conf2"><p>LY: Applied Biological Materials is a Science Exchange associated laboratory.</p></fn><fn fn-type="conflict" id="conf3"><p>The other authors declare that no competing interests exist.</p></fn><fn fn-type="conflict" id="conf4"><p>RP:CB: EI, FT, JL, NP: Employed and hold shares in Science Exchange Inc.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>VS, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>LY, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>MC, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>KO, Drafting or revising the article</p></fn><fn fn-type="con" id="con5"><p>RP:CB, Conception and design, Drafting or revising the article</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corcoran</surname><given-names>RB</given-names></name><name><surname>Dias-Santagata</surname><given-names>D</given-names></name><name><surname>Bergethon</surname><given-names>K</given-names></name><name><surname>Iafrate</surname><given-names>AJ</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation</article-title><source>Science Signaling</source><volume>3</volume><fpage>ra84</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2001148</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Clegg</surname><given-names>S</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Woffendin</surname><given-names>H</given-names></name><name><surname>Garnett</surname><given-names>MJ</given-names></name><name><surname>Bottomley</surname><given-names>W</given-names></name><name><surname>Davis</surname><given-names>N</given-names></name><name><surname>Dicks</surname><given-names>E</given-names></name><name><surname>Ewing</surname><given-names>R</given-names></name><name><surname>Floyd</surname><given-names>Y</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Hawes</surname><given-names>R</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>Kosmidou</surname><given-names>V</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Mould</surname><given-names>C</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Watt</surname><given-names>S</given-names></name><name><surname>Hooper</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Jayatilake</surname><given-names>H</given-names></name><name><surname>Gusterson</surname><given-names>BA</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Shipley</surname><given-names>J</given-names></name><name><surname>Hargrave</surname><given-names>D</given-names></name><name><surname>Pritchard-Jones</surname><given-names>K</given-names></name><name><surname>Maitland</surname><given-names>N</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><name><surname>Riggins</surname><given-names>GJ</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Cossu</surname><given-names>A</given-names></name><name><surname>Flanagan</surname><given-names>A</given-names></name><name><surname>Nicholson</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>JWC</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Seigler</surname><given-names>HF</given-names></name><name><surname>Darrow</surname><given-names>TL</given-names></name><name><surname>Paterson</surname><given-names>H</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mutations of the BRAF gene in human cancer</article-title><source>Nature</source><volume>417</volume><fpage>949</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1038/nature00766</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhomen</surname><given-names>N</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>BRAF signaling and targeted therapies in melanoma</article-title><source>Hematology/Oncology Clinics of North America</source><volume>23</volume><fpage>529</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2009.04.001</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>TM</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Gunn</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>FE</given-names></name><name><surname>Lomax</surname><given-names>J</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An open investigation of the reproducibility of cancer biology research</article-title><source>eLife</source><volume>3</volume><pub-id pub-id-type="doi">10.7554/eLife.04333</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>A-G</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behavior Research Methods</source><volume>39</volume><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/BF03193146</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedorenko</surname><given-names>IV</given-names></name><name><surname>Gibney</surname><given-names>GT</given-names></name><name><surname>Sondak</surname><given-names>VK</given-names></name><name><surname>Smalley</surname><given-names>KSM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Beyond BRAF: where next for melanoma therapy?</article-title><source>British Journal of Cancer</source><volume>112</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/bjc.2014.476</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>O'Dwyer</surname><given-names>PJ</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Grippo</surname><given-names>JF</given-names></name><name><surname>Nolop</surname><given-names>K</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Inhibition of mutated, activated BRAF in metastatic melanoma</article-title><source>New England Journal of Medicine</source><volume>363</volume><fpage>809</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1002011</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>D</given-names></name><name><surname>Salmeron</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cot/Tpl-2 protein kinase as a target for the treatment of inflammatory disease</article-title><source>Current Topics in Medicinal Chemistry</source><volume>9</volume><fpage>611</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.2174/156802609789007345</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inamdar</surname><given-names>GS</given-names></name><name><surname>Madhunapantula</surname><given-names>SV</given-names></name><name><surname>Robertson</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail</article-title><source>Biochemical Pharmacology</source><volume>80</volume><fpage>624</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2010.04.029</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Thomas</surname><given-names>SR</given-names></name><name><surname>Wardwell</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Emery</surname><given-names>CM</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Cogdill</surname><given-names>AP</given-names></name><name><surname>Barretina</surname><given-names>J</given-names></name><name><surname>Caponigro</surname><given-names>G</given-names></name><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Murray</surname><given-names>RR</given-names></name><name><surname>Salehi-Ashtiani</surname><given-names>K</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Alkan</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>JL</given-names></name><name><surname>Wilson</surname><given-names>CJ</given-names></name><name><surname>Myer</surname><given-names>VE</given-names></name><name><surname>Finan</surname><given-names>PM</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Golub</surname><given-names>T</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>COT drives resistance to RAF inhibition through MAP kinase pathway reactivation</article-title><source>Nature</source><volume>468</volume><fpage>968</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1038/nature09627</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakens</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs</article-title><source>Frontiers in Psychology</source><volume>4</volume><elocation-id>863</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyg.2013.00863</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Bergami</surname><given-names>P</given-names></name><name><surname>Fitchman</surname><given-names>B</given-names></name><name><surname>Ronai</surname><given-names>Ze’ev</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Understanding signaling cascades in melanoma</article-title><source>Photochemistry and Photobiology</source><volume>84</volume><fpage>289</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1111/j.1751-1097.2007.00254.x</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>KE</given-names></name><name><surname>Pritchard</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Raf proteins and cancer: B-Raf is identified as a mutational target</article-title><source>Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer</source><volume>1653</volume><fpage>25</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S0304-419X(03)00016-7</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaloglou</surname><given-names>C</given-names></name><name><surname>Vredeveld</surname><given-names>LCW</given-names></name><name><surname>Mooi</surname><given-names>WJ</given-names></name><name><surname>Peeper</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>BRAFE600 in benign and malignant human tumours</article-title><source>Oncogene</source><volume>27</volume><fpage>877</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210704</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panka</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Targeting the mitogen-activated protein kinase pathway in the treatment of Malignant melanoma</article-title><source>Clinical Cancer Research</source><volume>12</volume><fpage>2371s</fpage><lpage>2375</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2539</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paraiso</surname><given-names>KHT</given-names></name><name><surname>Haarberg</surname><given-names>HE</given-names></name><name><surname>Wood</surname><given-names>E</given-names></name><name><surname>Rebecca</surname><given-names>VW</given-names></name><name><surname>Chen</surname><given-names>YA</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Sondak</surname><given-names>VK</given-names></name><name><surname>John</surname><given-names>JK</given-names></name><name><surname>Sarnaik</surname><given-names>AA</given-names></name><name><surname>Koomen</surname><given-names>JM</given-names></name><name><surname>Smalley</surname><given-names>KSM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms</article-title><source>Clinical Cancer Research</source><volume>18</volume><fpage>2502</fpage><lpage>2514</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2612</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Hong</surname><given-names>S-W</given-names></name><name><surname>Moon</surname><given-names>J-H</given-names></name><name><surname>Jin</surname><given-names>D-H</given-names></name><name><surname>Kim</surname><given-names>J-S</given-names></name><name><surname>Lee</surname><given-names>C-K</given-names></name><name><surname>Kim</surname><given-names>Kyu-pyo</given-names></name><name><surname>Hong</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>J-L</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Choi</surname><given-names>EK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human Malignant melanoma cells</article-title><source>The American Journal of the Medical Sciences</source><volume>346</volume><fpage>494</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1097/MAJ.0b013e318298a185</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schayowitz</surname><given-names>A</given-names></name><name><surname>Bertenshaw</surname><given-names>G</given-names></name><name><surname>Jeffries</surname><given-names>E</given-names></name><name><surname>Schatz</surname><given-names>T</given-names></name><name><surname>Cotton</surname><given-names>J</given-names></name><name><surname>Villanueva</surname><given-names>J</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Krepler</surname><given-names>C</given-names></name><name><surname>Vultur</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>GH</given-names></name><name><surname>Schuchter</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Functional profiling of live melanoma samples using a novel automated platform</article-title><source>PLoS ONE</source><volume>7</volume><elocation-id>e52760</elocation-id><elocation-id>e52760</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0052760</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>MA</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>AK</given-names></name><name><surname>Amin</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Robertson</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases</article-title><source>Cancer Research</source><volume>66</volume><fpage>8200</fpage><lpage>8209</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0809</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shtivelman</surname><given-names>E</given-names></name><name><surname>Davies</surname><given-names>MA</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Lotem</surname><given-names>M</given-names></name><name><surname>Oren</surname><given-names>M</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Fisher</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pathways and therapeutic targets in melanoma</article-title><source>Oncotarget</source><volume>5</volume><fpage>1701</fpage><lpage>1752</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.1892</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalley</surname><given-names>KS</given-names></name><name><surname>Haass</surname><given-names>NK</given-names></name><name><surname>Brafford</surname><given-names>PA</given-names></name><name><surname>Lioni</surname><given-names>M</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases</article-title><source>Molecular Cancer Therapeutics</source><volume>5</volume><fpage>1136</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0084</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalley</surname><given-names>K</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Towards the targeted therapy of melanoma</article-title><source>Mini-Reviews in Medicinal Chemistry</source><volume>6</volume><fpage>387</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.2174/138955706776361402</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Team</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2015">2015</year><source>R: A Language and Environment for Statistical Computing</source><publisher-name>R Foundation for Statistical Computing</publisher-name><uri xlink:href="http://www.R-project.org/">http://www.R-project.org/</uri></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villanueva</surname><given-names>J</given-names></name><name><surname>Vultur</surname><given-names>A</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Resistance to BRAF inhibitors: Unraveling mechanisms and future treatment options</article-title><source>Cancer Research</source><volume>71</volume><fpage>7137</fpage><lpage>7140</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1243</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.11414.003</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hunter</surname><given-names>Tony</given-names></name><role>Reviewing editor</role><aff id="aff5"><institution>Salk Institute</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your work entitled &quot;Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation&quot; for consideration by <italic>eLife</italic>. Your submission has been evaluated by Tony Hunter who has reviewed the protocols presented. We would ask to make to address the following comments before peer review:</p><p>1) In Protocol 4, the authors state &quot;This experiment assesses the effect of the COT kinase inhibitor, TPL2, has on the MAPK pathway, in cells expressing elevated COT, as analyzed via Western blot.&quot; This leads me to believe that the authors are unaware that TPL2 is another name for COT, which is an ongoing confusion in the literature, and, from the start of the report, they need to clarify that COT and TPL2 are the same thing, both of which have the formal name MAP3K8. The authors of the paper being replicated obtained the TPL2/COT/MAP3K8 inhibitor from EMD Millipore, whereas the authors plan to obtain the TPL2/COT inhibitor from Santa Cruz rather than EMD Millipore. However, two compounds from the two companies have slightly different structures (i.e. EMD sells: 4-(cycloheptylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-[1,7]-naphthyridine, whereas Santa Cruz sell: 4-(3-chloro-4-fluorophenylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-[1,7]-naphthyridine, as their TPL2/COT inhibitor (sc-204351). This may not make a difference, but the authors will need to validate sc-204351 to show it has the expected ability to inhibit TPL2/COT kinase activity at the concentrations they are planning to use.</p><p>2) In Protocols 5 and 6, the authors plan to generate A375 cells expressing exogenous MEK1, MEK1<sup>DD</sup> and MAP3K8/COT using lentivirus expression vector infection and blasticidin drug selection. However, they do not plan to ensure that the infected cells are actually expressing the kinase of interest at elevated levels, and this is obviously essential to do, so that the consequences of treatment with PLX4720 can be properly interpreted.</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><p>Thank you for submitting your work entitled &quot;Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation&quot; for peer review at <italic>eLife</italic>. We apologize for the long delay in reaching this decision, but there was difficulty in finding qualified reviewers. Your submission has been favorably evaluated by Tony Hunter (Senior Editor) and two reviewers.</p><p>Reviewer 2 was satisfied, and therefore I have only included below the comments of Reviewer 1. As you will see the reviewer's comments mostly pertain to improving the quality of the experiments and the validity of the conclusions that can be drawn from them. Since the goal of a Registered Report is to replicate the original studies, you are not required to include the additional experiments, but if you believe that any of the suggested experiments would strengthen the conclusions and can readily be incorporated, perhaps as separate data panels, then you could do so. Please let me know your plans for proceeding with the experimental studies for the Registered Report.</p><p><italic>Reviewer 1:</italic></p><p>The Registered Report aims to repeat key experiments from the 2010 study of Johnanessen et al. which proposed that COT/TPL2 can drive the resistance of B-RAF[V600E] transformed cell lines to a selective RAF kinase inhibitor. COT/TPL2 was identified in an overexpression screen for genes that promote survival of A375 cultured with the specific RAF inhibitor PLX4720. This initial result is unsurprising given that is well established (in papers published over a decade earlier) that COT/TPL2 functions as a MKK1/2 kinase (similar to RAF kinases) and is constitutively active when overexpressed.</p><p>Proposed experiments:</p><p>The original paper proposed that overproduction of endogenous COT/TPL2 drives resistance of malignant melanomas to PLX4720. However, this conclusion was largely based on experiments with one malignant melanoma line, RPMI-7951 in which COT/TPL2 levels are relatively high. The impact of the study would have been greater if other RAF[V600E] transformed cell lines with COT/TPL2 overexpression had been analyzed in detail as per RPMI-7951 cells.</p><p>Protocol 1 (Figures 3B and 3E)</p><p>The effect of a range of concentrations of PLX4720 will be tested on the A375 and RPMI-7951 cell lines. Activation of the MKK1/2 &gt; ERK1/2 MAP kinase pathway will be monitored by immunoblotting.</p><p>The original Figure 3E tests the effect of PLX4720 on A375, OUMS-23 and RPMI-7951. For the replication study, it is important that OUMS-23 cells, which express very high levels of COT/TPL2, are added to the proposed experiments to determine whether ERK1/2 phosphorylation is maintained in these cells after PLX4720 treatment. As noted above, a limitation of the original study was the dependence on very few cell lines, making generalization of results difficult.</p><p>Cell lysate will be resolved by SDS-PAGE and immunoblotted for pERK1/2, total ERK1/2, pMKK1/2, total MKK1/2, COT/TPL-2 and actin. From the protocol, three combinations of antibodies will be tested, presumably in three separate gels (although this is not clear). In our experience, probing blots with pERK1/2 antibody interferes with subsequent probing for total ERK1/2, even after antibody stripping. Consequently, it is better to probe for pERK1/2 and MKK1/2 on one blot and for pMKK1/2 and ERK1/2 on another.</p><p>It is planned to use HRP-coupled secondary antibodies and ECL for immunoblotting. However, the linear range of ECL is relatively small and it would be much better to quantify bands using IR Dye-labeled secondary antibodies and a LI-COR scanner. This was also true when the original experiments were carried out.</p><p>Protocol 3</p><p>This protocol will test the effect of PLX4720 on the viability of A375 and RPMI-7951 cells. However, the experiment shown in Figure 3D of the original paper tested the effect of PLX4720 on a panel of cells lines, with low or high COT/TPL2 expression. Since the authors are making general claims about the role of COT/TPL2 in resistance to RAF inhibitors, OUMS-23 should be analyzed as well. The inclusion of a cell line with low COT/TPL2 levels, similar to A375, would also be preferable.</p><p>Protocol 4</p><p>The authors have used a Wyeth COT/TPL2 small molecule inhibitor to determine whether COT/TPL2 signaling is required for MKK1/2 and ERK1/2. Our experience some of the early Wyeth compounds is that they have clear off-target effects (revealed by testing their effect on cytokine production in LPS-stimulated <italic>Map3k8</italic>-/- macrophages). The significance of the experiment shown in Figure 3I therefore is highly questionable. In addition, since the effects of the inhibitor on are only partial, pMKK1/2 and pERK1/2 levels in the original study should have been quantified from multiple experiments and differences tested for statistical significance (as noted in the Registered Report proposal). In view of the limitations of the COT/TPL2 inhibitor experiment, it is important that the siRNA knockdown experiment in Figure 3H is repeated. For this, it is essential to correlate reduction in pERK1/2 levels with the degree of COT/TPL2 knockdown achieved with shCOT-1 and shCOT-2.</p><p>See comments on Protocol 2 regarding lysis buffer, immunoblotting etc.</p><p>Comment</p><p>In Figure 4C, why are A375 cells expressing MEK1<sup>DD</sup> sensitive to RAF265 inhibitor? Similarly, with SKMEL28 cells expressing MEK1<sup>DD</sup>. I could find no reference to these results in the text. I would have expected MEK1<sup>DD</sup> expression in A375 cells to bypass the requirement for constitutive RAF signaling. Am I missing something?</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.11414.004</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>1) In Protocol 4, the authors state &quot;This experiment assesses the effect of the COT kinase inhibitor, TPL2, has on the MAPK pathway, in cells expressing elevated COT, as analyzed via Western blot.&quot; This leads me to believe that the authors are unaware that TPL2 is another name for COT, which is an ongoing confusion in the literature, and, from the start of the report, they need to clarify that COT and TPL2 are the same thing, both of which have the formal name MAP3K8. The authors of the paper being replicated obtained the TPL2/COT/MAP3K8 inhibitor from EMD Millipore, whereas the authors plan to obtain the TPL2/COT inhibitor from Santa Cruz rather than EMD Millipore. However, two compounds from the two companies have slightly different structures (i.e. EMD sells: 4-(cycloheptylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-[1,7]-naphthyridine, whereas Santa Cruz sell: 4-(3-chloro-4-fluorophenylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-[1,7]-naphthyridine, as their TPL2/COT inhibitor (sc-204351). This may not make a difference, but the authors will need to validate sc-204351 to show it has the expected ability to inhibit TPL2/COT kinase activity at the concentrations they are planning to use.</italic></p><p>Thank you for the suggestion about the protein name. We have gone through the manuscript and defined in the Introduction all the names used for the protein of interest and for consistency are using the formal name MAP3K8 from that point on. We used the same name that was used in the original publication for each experiment/figure/reagent in an attempt to make the comparison easier to follow, but agree it is better to not add to the ongoing confusion in the literature.</p><p>Regarding the inhibitor, we have switched the inhibitor that will be used to the EMD source to minimize differences from the original experiment. However, the EMD source originally used, and now planned to be used in the replication attempt, is the same compound as the Santa Cruz source we had originally suggested (4-(3-chloro-4-fluorophenylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-[1,7]-naphthyridine; CAS number: 871307-18-5. EMD also has the type II MAP3K8 kinase inhibitor (4-(cycloheptylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-[1,7]-naphthyridine; CAS number: 1186649-59-4), however this molecule is not being utilized in the replication attempt as it was not used in the original experiment.</p><p> <italic>2) In Protocols 5 and 6, the authors plan to generate A375 cells expressing exogenous MEK1, MEK1<sup>DD</sup> and MAP3K8/COT using lentivirus expression vector infection and blasticidin drug selection. However, they do not plan to ensure that the infected cells are actually expressing the kinase of interest at elevated levels, and this is obviously essential to do, so that the consequences of treatment with PLX4720 can be properly interpreted.</italic></p><p>The expression of the exogenous proteins will be assessed by western blot using an antibody against the V5 tag, which is included in the vectors for expression of MEK1, MEK1<sup>DD</sup>, and MAP3K8. We have more clearly described this in the revised manuscript. Additionally, in the revised manuscript we are also including antibodies against MAP3K8 and MEK1 to assess the relative degree of elevated protein levels by western blot.</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><p><italic>Reviewer 2 was satisfied, and therefore I have only included below the comments of Reviewer 1. As you will see the reviewer's comments mostly pertain to improving the quality of the experiments and the validity of the conclusions that can be drawn from them. Since the goal of a Registered Report is to replicate the original studies, you are not required to include the additional experiments, but if you believe that any of the suggested experiments would strengthen the conclusions and can readily be incorporated, perhaps as separate data panels, then you could do so. Please let me know your plans for proceeding with the experimental studies for the Registered Report. Reviewer 1:</italic></p><p><italic>Proposed experiments: The original paper proposed that overproduction of endogenous COT/TPL2 drives resistance of malignant melanomas to PLX4720. However, this conclusion was largely based on experiments with one malignant melanoma line, RPMI-7951 in which COT/TPL2 levels are relatively high. The impact of the study would have been greater if other RAF[V600E] transformed cell lines with COT/TPL2 overexpression had been analyzed in detail as per RPMI-7951 cells. Protocol 1 (Figures 3B and 3E) The effect of a range of concentrations of PLX4720 will be tested on the A375 and RPMI-7951 cell lines. Activation of the MKK1/2 &gt; ERK1/2 MAP kinase pathway will be monitored by immunoblotting.</italic></p><p> <italic>The original Figure 3E tests the effect of PLX4720 on A375, OUMS-23 and RPMI-7951. For the replication study, it is important that OUMS-23 cells, which express very high levels of COT/TPL2, are added to the proposed experiments to determine whether ERK1/2 phosphorylation is maintained in these cells after PLX4720 treatment. As noted above, a limitation of the original study was the dependence on very few cell lines, making generalization of results difficult.</italic></p><p>Thank you for this suggestion. We agree and have added the OUMS-23 cell line in the revised manuscript. We have also adjusted the analysis plans and power calculations to reflect the analysis of OUMS-23 cells similar to A375 and RPMI-7951.</p><p> <italic>Cell lysate will be resolved by SDS-PAGE and immunoblotted for pERK1/2, total ERK1/2, pMKK1/2, total MKK1/2, COT/TPL-2 and actin. From the protocol, three combinations of antibodies will be tested, presumably in three separate gels (although this is not clear). In our experience, probing blots with pERK1/2 antibody interferes with subsequent probing for total ERK1/2, even after antibody stripping. Consequently, it is better to probe for pERK1/2 and MKK1/2 on one blot and for pMKK1/2 and ERK1/2 on another.</italic></p><p>We have clarified the protocols where multiple gels are run to indicate the intention of running three separate gels. We have also changed the probing of the blots to reflect this strategy. As a result, we have also changed the cat # of the total ERK1/2 and MEK1/2 antibodies to a different species (opposite what pERK1/2 and pMEK1/2 are) in addition to the normalization strategy to reflect what is probed on the same blot.</p><p> <italic>It is planned to use HRP-coupled secondary antibodies and ECL for immunoblotting. However, the linear range of ECL is relatively small and it would be much better to quantify bands using IR Dye-labeled secondary antibodies and a LI-COR scanner. This was also true when the original experiments were carried out.</italic></p><p>We agree that IR Dye-labeled secondary antibodies and a LI-COR scanner are ideal and the linear range of ECL is relatively small. While the lab is not equipped with a LI-COR scanner we will make all the exposures from ECL publicly available. There is also the possibility the lab might be able to access a nearby scanner. We have added a statement in the manuscript to indicate that if a LI-COR scanner is available it will be used instead of the ECL approach, with the HRP coupled secondary antibodies switched for the appropriate IR Dye-labeled secondary antibodies. This does not impact the proposed analysis plan. If the antibody detection is performed with the LI-COR scanner, it will also be made transparent in the Replication Study.</p><p> <italic>Protocol 3 This protocol will test the effect of PLX4720 on the viability of A375 and RPMI-7951 cells. However, the experiment shown in Figure 3D of the original paper tested the effect of PLX4720 on a panel of cells lines, with low or high COT/TPL2 expression. Since the authors are making general claims about the role of COT/TPL2 in resistance to RAF inhibitors, OUMS-23 should be analyzed as well. The inclusion of a cell line with low COT/TPL2 levels, similar to A375, would also be preferable.</italic></p><p>Thank you for this suggestion. We agree and have added the OUMS-23 cell line in the revised manuscript for Protocol 2 as well as Protocol 3. We have also adjusted the analysis plans and power calculations to reflect the analysis of OUMS-23 cells similar to A375 and RPMI-7951.</p><p><italic>Protocol 4 The authors have used a Wyeth COT/TPL2 small molecule inhibitor to determine whether COT/TPL2 signaling is required for MKK1/2 and ERK1/2. Our experience some of the early Wyeth compounds is that they have clear off-target effects (revealed by testing their effect on cytokine production in LPS-stimulated Map3k8-/- macrophages). The significance of the experiment shown in Figure 3I therefore is highly questionable. In addition, since the effects of the inhibitor on are only partial, pMKK1/2 and pERK1/2 levels in the original study should have been quantified from multiple experiments and differences tested for statistical significance (as noted in the Registered Report proposal). In view of the limitations of the COT/TPL2 inhibitor experiment, it is important that the siRNA knockdown experiment in Figure 3H is repeated. For this, it is essential to correlate reduction in pERK1/2 levels with the degree of COT/TPL2 knockdown achieved with shCOT-1 and shCOT-2.</italic></p><p> <italic>See comments on Protocol 2 regarding lysis buffer, immunoblotting etc.</italic></p><p>We agree that including the shCOT experiment would be of interest considering the limitations of the COT/TPL2 inhibitor experiment and by excluding it limits the scope of what can be interpreted from this replication attempt, but we are attempting to identify a balance of breadth of sampling for general inference with sensible investment of resources on replication projects. While the COT/TPL2 small molecular inhibitor has off-target effects, our anticipation is that the proposed quantification and statistical tests will further evaluate whether this inhibitor has an effect on pMEK1/2 and pERK1/2 levels, whether directly or indirectly through COT/TPL2.</p><p> <italic>Comment In Figure 4C, why are A375 cells expressing MEK1<sup>DD</sup> sensitive to RAF265 inhibitor? Similarly, with SKMEL28 cells expressing MEK1<sup>DD</sup>. I could find no reference to these results in the text. I would have expected MEK1<sup>DD</sup> expression in A375 cells to bypass the requirement for constitutive RAF signaling. Am I missing something?</italic></p><p>We agree with the reviewer that this seems to be an interesting observation made by the original lab even though it wasn’t discussed and should be investigated by future replication efforts.</p></body></sub-article></article>